

10/816,161 ALW

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	30	Feb 26	MEDLINE reloaded with enhancements
NEWS	31	Feb 26	EMBASE enhanced with Clinical Trial Number field
NEWS	32	Feb 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	33	Feb 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	34	Feb 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),

10/816,161 ALW

AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:30:32 ON 04 MAR 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 08:30:40 ON 04 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3

DICTIONARY FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10816161ALW.str



chain nodes :

8 14

ring nodes :

1 2 3 4 5 6 9 10 11 12 13

chain bonds :

1-9 2-8 11-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-13 10-11 11-12 12-13

exact/norm bonds :

1-2 1-6 1-9 2-3 2-8 3-4 4-5 5-6

exact bonds :

9-10 9-13 10-11 11-12 11-14 12-13

isolated ring systems :

containing 1 : 9 :

G1:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:CLASS


10/816,161 ALW

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 08:31:02 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2801 TO ITERATE

71.4% PROCESSED 2000 ITERATIONS

4 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 52846 TO 59194

PROJECTED ANSWERS: 4 TO 254


L2 4 SEA SSS SAM L1

=> d scan

10/816,161 ALW

L2 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1,3,5-Triazine-1(2H)-sulfonic acid, 6-amino-3,4-dihydro-4-oxo-3- $\beta$ -D-  
ribofuranosyl- (9CI)  
MF C8 H14 N4 O8 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

10/816,161 ALW

L2 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1,3,5-Triazin-2(1H)-one, 6-amino-4-methyl-1-(2,3,5-tri-O-benzoyl- $\beta$ -D-  
ribofuranosyl)- (9CI)  
MF C30 H26 N4 O8

Absolute stereochemistry. Rotation (+).




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/816,161 ALW

L2 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1,3,5-Triazin-2(1H)-one, 4,6-diamino-1- $\beta$ -D-ribofuranosyl- (9CI)  
MF C8 H13 N5 O5

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/816,161 ALW

L2 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1-[5-O-(methylsulfonyl)- $\beta$ -D-  
ribofuranosyl]- (9CI)  
MF C9 H15 N3 O8 S

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED



10/816,161 ALW

=> s l1 sss ful

FULL SEARCH INITIATED 08:31:24 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 56666 TO ITERATE

100.0% PROCESSED 56666 ITERATIONS  
SEARCH TIME: 00.00.01

132 ANSWERS

L3 132 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
172.10	172.31

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 08:31:30 ON 04 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Mar 2007 VOL 146 ISS 11

FILE LAST UPDATED: 2 Mar 2007 (20070302/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 143 L3


=> d l4 1-143 bib hitstr

10/816,161 ALW

L4 ANSWER 1 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2007:173724 CAPLUS  
TI Anti-angiogenic use of inhibitors of DNA methyltransferase and histone deacetylase after diagnosing the decrease in expression of neovascularization-specific biomarkers  
IN Van Engeland, Manon; Griffioen, Arjan W.  
PA Oncomethylome Sciences S. A., Belg.  
SO PCT Int. Appl., 101pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007017065	A2	20070215	WO 2006-EP7092	20060719
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	GB 2005-15471	A	20050727		
	US 2005-702582P	P	20050727		
IT	INDEXING IN PROGRESS				
IT	62488-57-7, 5,6-Dihydro-5-azacytidine				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(DNMT inhibitor; anti-angiogenic use of inhibitors of DNA methyltransferase and histone deacetylase after diagnosing decrease in expression of neovascularization-specific biomarkers)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-				
	(9CI) (CA INDEX NAME)				

Absolute stereochemistry.




10/816,161 ALW

L4 ANSWER 2 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2007:150677 CAPLUS  
DN 146:201596  
TI Trans-differentiation of fibroblasts into hematopoietic and endothelial  
cells using demethylating agents, and cell therapy applications  
IN Estrov, Zeev; Strassman, Gideon  
PA Board of Regents, The University of Texas System, USA  
SO PCT Int. Appl., 49pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007016037	A2	20070208	WO 2006-US28701	20060724
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2005-702749P	P	20050727		
	US 2005-729708P	P	20051024		
	US 2005-734864P	P	20051109		
IT	114522-16-6				
	RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)				
	(demethylating agent; trans-differentiation of fibroblasts into hematopoietic and endothelial cells using demethylating agents, and cell therapy applications)				
RN	114522-16-6 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



L4 ANSWER 3 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:1062676 CAPLUS  
 DN 145:417043  
 TI Combined therapy utilizing reduction of DNA methyltransferase expression and/or activity and interferon  
 IN Borden, Ernest; Reu, Frederic; Macleod, A.; Reid, Gregory; Besterman, Jeffrey  
 PA Methylgene, Inc., Can.; The Cleveland Clinic Foundation  
 SO PCT Int. Appl., 43pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006107751	A2	20061012	WO 2006-US11942	20060330
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 2006252723	A1	20061109	US 2006-393380	20060330
PRAI	US 2005-667285P	P	20050401		
IT	62488-57-7, 5,6-Dihydro-5-azacytidine				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(combined cancer therapy utilizing reduction of DNA methyltransferase expression and/or activity and interferon)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-				
	(9CI) (CA INDEX NAME)				

Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 4 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:885316 CAPLUS

DN 145:290485

TI Marker genes to predict the sensitivity of tumor cells to cytotoxic agents in the selection of chemotherapies

IN Sadee, Wolfgang; Huang, Ying

PA The Ohio State University Research Foundation, USA

SO PCT Int. Appl., 98pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006091969	A2	20060831	WO 2006-US7045	20060227
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2005-656195P	P	20050225		
IT	62488-57-7, 5,6-Dihydro-5-azacytidine				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(determination of resistance and sensitivity to; marker genes to predict sensitivity of tumor cells to cytotoxic agents in selection of chemotherapies)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-				
	(9CI) (CA INDEX NAME)				

Absolute stereochemistry.




10/816,161 ALW

L4 ANSWER 5 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:438068 CAPLUS  
DN 144:445342  
TI Syk protein kinase and/or SHP-1 protein phosphatase-based method for  
increasing efficacy of tumor cell killing using combinations of  
antineoplastic agents  
IN Ball, Edward D.; Balaian, Larissa  
PA Regents of the University of California, USA  
SO PCT Int. Appl., 63 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006050075	A2	20060511	WO 2005-US38904	20051028
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2004-623060P	P	20041029		
IT	62488-57-7, 5,6-Dihydro-5-azacytidine				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(Syk protein kinase and/or SHP-1 protein phosphatase-based method for increasing efficacy of tumor cell killing using combinations of antineoplastic agents)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-				
	(9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L4 ANSWER 6 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:360483 CAPLUS  
DN 144:403693  
TI Characterization of decomposition products and preclinical and low dose  
clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new  
liquid chromatography/tandem mass spectrometry quantification method  
AU Liu, Zhongfa; Marcucci, Guido; Byrd, John C.; Grever, Michael; Xiao, Jim;  
Chan, Kenneth K.  
CS College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA  
SO Rapid Communications in Mass Spectrometry (2006), 20(7), 1117-1126  
CODEN: RCMSEF; ISSN: 0951-4198  
PB John Wiley & Sons Ltd.  
DT Journal  
LA English  
IT 62488-57-7P, 5,6-Dihydro-5-azacytidine  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(decitabine decomposition products, pharmacokinetics, and liquid  
chromatog./tandem mass spectrometry quantification method)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

L4 ANSWER 7 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:100738 CAPLUS  
DN 144:198849  
TI Novel dosage form comprising modified-release and immediate-release active ingredients  
IN Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar  
PA India  
SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006024365	A1	20060202	US 2005-134633	20050519
	IN 193042	A1	20040626	IN 2002-MU697	20020805
	US 2004096499	A1	20040520	US 2003-630446	20030729
PRAI	IN 2002-MU697	A	20020805		
	IN 2002-MU699	A	20020805		
	IN 2003-MU80	A	20030122		
	IN 2003-MU82	A	20030122		
	US 2003-630446	A2	20030729		
IT	62488-57-7				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (novel dosage form comprising modified-release and immediate-release active ingredients)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl- (9CI) (CA INDEX NAME)				


. Absolute stereochemistry.






L4 ANSWER 8 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:64429 CAPLUS  
 DN 144:307309  
 TI Physical Nature of Interactions within the Active Site of  
 Cytosine-5-methyltransferase  
 AU Forde, Gareth K.; Kedzierski, Pawel; Sokalski, W. Andrzej; Forde, Aviane  
 E.; Hill, Glake A.; Leszczynski, Jerzy  
 CS Computational Center for Molecular Structure and Interactions, Jackson  
 State University, Jackson, MS, 392171, USA  
 SO Journal of Physical Chemistry A (2006), 110(6), 2308-2313  
 CODEN: JPCAFH; ISSN: 1089-5639  
 PB American Chemical Society  
 DT Journal  
 LA English  
 IT 879506-82-8 879506-87-3  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
 (Biological study)  
 (electrostatic interactions associated with active site residues Glu119,  
 Arg163, and Arg165 have critical role in stabilizing protonated transition  
 state structure of HhaI)  
 RN 879506-82-8 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-5-O-phosphono- $\beta$ -D-erythro-  
 pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879506-87-3 CAPLUS  
 CN 1,3,5-Triazin-2-ol, 4-amino-1-(2-deoxy-5-O-phosphono- $\beta$ -D-erythro-  
 pentofuranosyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 9 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1151314 CAPLUS  
 DN 145:397716  
 TI Synthesis and biological evaluation of conformationally restricted and nucleobase-modified analogs of the anticancer compound 3'-C-ethynylcytidine (ECYD)  
 AU Hrdlicka, Patrick J.; Jepsen, Jan S.; Wengel, Jesper  
 CS Nucleic Acid Center, Department of Chemistry, University of Southern Denmark, Odense M, Den.  
 SO Nucleosides, Nucleotides & Nucleic Acids (2005), 24(5-7), 397-400  
 CODEN: NNNAFY; ISSN: 1525-7770  
 PB Taylor & Francis, Inc.  
 DT Journal  
 LA English  
 OS CASREACT 145:397716  
 IT 848644-57-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and anticancer activity of ethynyl-substituted nucleosides via glycosylation)  
 RN 848644-57-5 CAPLUS  
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(3-C-ethynyl- $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 848644-47-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and anticancer activity of ethynyl-substituted nucleosides via glycosylation)  
 RN 848644-47-3 CAPLUS  
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(2,3,5-tri-O-acetyl-3-C-ethynyl- $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 9  
 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW


L4 ANSWER 10 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1081646 CAPLUS  
 DN 145:249427  
 TI Preparation of 2'-deoxynucleosides of cyanuric acid for their inclusion in DNA oligonucleotides  
 AU Panagopoulos, Dimitris; Salgado, Antonio; Gimisis, Thanasis  
 CS Organic Chemistry Laboratory, Department of Chemistry, University of Athens, Athens, 15771, Greece  
 SO Collection Symposium Series (2005), 7(Chemistry of Nucleic Acid Components), 449-451  
 CODEN: CSYSFN  
 PB Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic  
 DT Journal  
 LA English  
 OS CASREACT 145:249427  
 IT 22432-96-8P 22432-99-1P 70165-41-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of 2'-deoxynucleosides of cyanuric acid via radical deoxygenation for use toward the preparation of DNA oligonucleotides)  
 RN 22432-96-8 CAPLUS  
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-β-D-ribofuranosyl- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 22432-99-1 CAPLUS  
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 70165-41-2 CAPLUS  
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(2-deoxy-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

10/816,161 ALW

Absolute stereochemistry.



IT 243646-85-7P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of 2'-deoxynucleosides of cyanuric acid via radical deoxygenation for use toward the preparation of DNA oligonucleotides)

RN 243646-85-7 CAPLUS

CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-2-deoxy- $\beta$ -D-erythro-pentofuranosyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:998719 CAPLUS

DN 143:279361

TI Aryl compound inhibitors of DNA methylation in tumor cells, and therapeutic and other uses thereof

IN Garcia Boy, Regine; Lyko, Frank; Siedlecki, Pawel

PA DKFZ Deutsches Krebsforschungszentrum, Germany

SO Eur. Pat. Appl., 30 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1574499	A1	20050914	EP 2004-5498	20040308
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	CA 2557581	A1	20050915	CA 2005-2557581	20050308
	WO 2005085196	A2	20050915	WO 2005-EP2437	20050308
	WO 2005085196	A3	20051208		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1725531	A2	20061129	EP 2005-715834	20050308
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	EP 2004-5498	A	20040308		
	EP 2004-14619	A	20040622		
	WO 2005-EP2437	W	20050308		
OS	MARPAT 143:279361				
IT	62488-57-7, 5,6-Dihydro-5-azacytidine				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(aryl compound DNA methylation inhibitors, and use with other agents)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-				
	(9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

10/816,161 ALW

L4 ANSWER 12 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:696887 CAPLUS

DN 143:194107

TI Pyrimidyl phosphonate antiviral compounds and methods of use

IN Jin, Haolun; Kim, Choung U.

PA Gilead Sciences, Inc., USA

SO PCT Int. Appl., 170 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005070901	A2	20050804	WO 2005-US815	20050111
	WO 2005070901	A3	20060504		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,			SM
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005206511	A1	20050804	AU 2005-206511	20050111
	CA 2552584	A1	20050804	CA 2005-2552584	20050111
	US 2005282839	A1	20051222	US 2005-33422	20050111
	EP 1711476	A2	20061018	EP 2005-705460	20050111
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
PRAI	US 2004-536010P	P	20040112		
	WO 2005-US815	W	20050111		
OS	MARPAT 143:194107				
IT	62488-57-7, 5,6-Dihydro-5-azacytidine				
	RL: BCP (Biochemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)				
	(preparation of pyrimidyl phosphonate antiviral compds. and methods of use)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-				
	(9CI) (CA INDEX NAME)				

Absolute stereochemistry.






10/816,161 ALW

L4 ANSWER 13 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:512844 CAPLUS  
DN 143:259549  
TI Mechanism of action of a novel viral mutagenic covert nucleotide:  
molecular interactions with HIV-1 reverse transcriptase and host cell DNA  
polymerases  
AU Murakami, Eisuke; Basavapathruni, Aravind; Bradley, William D.; Anderson,  
Karen S.  
CS Department of Pharmacology, Yale University School of Medicine, New Haven,  
CT, 06520-8066, USA  
SO Antiviral Research (2005), 67(1), 10-17  
CODEN: ARSRDR; ISSN: 0166-3542  
PB Elsevier B.V.  
DT Journal  
LA English  
IT 114522-16-6, KP 1212  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(mechanism of action of antiviral mutagenic KP-1212)  
RN 114522-16-6 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy- $\beta$ -D-erythro-  
pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

L4 ANSWER 14 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:512843 CAPLUS  
DN 143:259548  
TI KP-1212/1461, a nucleoside designed for the treatment of HIV by viral  
mutagenesis  
AU Harris, Kevin S.; Brabant, William; Styrchak, Sheila; Gall, Alexander;  
Daifuku, Richard  
CS Koronis Pharmaceuticals Inc., Redmond, WA, 98052, USA  
SO Antiviral Research (2005), 67(1), 1-9  
CODEN: ARSRDR; ISSN: 0166-3542  
PB Elsevier B.V.  
DT Journal  
LA English  
IT 114522-16-6, KP 1212  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological  
activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(KP-1212/1461 for treatment of HIV by viral mutagenesis)  
RN 114522-16-6 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy- $\beta$ -D-erythro-  
pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 15 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:69150 CAPLUS  
 DN 142:336570  
 TI Synthesis and biological evaluation of nucleobase-modified analogs of the anticancer compounds 3'-C-ethynyluridine (EURd) and 3'-C-ethynylcytidine (ECyd)  
 AU Hrdlicka, Patrick J.; Jepsen, Jan S.; Nielsen, Claus; Wengel, Jesper  
 CS Nucleic Acid Center, Department of Chemistry, University of Southern Denmark, Odense M, DK-5230, Den.  
 SO Bioorganic & Medicinal Chemistry (2005), 13(4), 1249-1260  
 CODEN: BMECEP; ISSN: 0968-0896  
 PB Elsevier Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 142:336570  
 IT 848644-47-3P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation, antiviral and antitumor activities of nucleobase-modified analogs of 3'-C-ethynyluridine and 3'-C-ethynylcytidine)  
 RN 848644-47-3 CAPLUS  
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(2,3,5-tri-O-acetyl-3-C-ethynyl- $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 848644-57-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation, antiviral and antitumor activities of nucleobase-modified analogs of 3'-C-ethynyluridine and 3'-C-ethynylcytidine)  
 RN 848644-57-5 CAPLUS  
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(3-C-ethynyl- $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD


10/816,161 ALW

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:1156447 CAPLUS  
 DN 142:86692  
 TI Prodrugs of heteroaryl compounds for the treatment of viral infection and cancer  
 IN Daifuku, Richard; Gall, Alexander; Sergueev, Dmitri; Sologub, Dina; Harris, Kevin  
 PA Koronis Pharmaceuticals, Incorporated, USA  
 SO PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004112716	A2	20041229	WO 2004-US19520	20040618
	WO 2004112716	A3	20050210		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005014752	A1	20050120	US 2004-816161	20040331
	AU 2004249245	A1	20041229	AU 2004-249245	20040618
	CA 2529500	A1	20041229	CA 2004-2529500	20040618
	EP 1635836	A2	20060322	EP 2004-755606	20040618
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-480037P	P	20030620		
	WO 2004-US19520	W	20040618		
OS	MARPAT 142:86692				
IT	815588-83-1P 815588-84-2P 815588-85-3P 815588-86-4P 815588-87-5P 815588-88-6P 815588-89-7P 815588-90-0P 815588-91-1P 815588-92-2P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(hydrophobic prodrugs of bases, nucleosides, and nucleotides for treatment of viral infection and cancer)				
RN	815588-83-1 CAPLUS				
CN	Carbamic acid, [5-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-1,4,5,6-tetrahydro-4-oxo-1,3,5-triazin-2-yl]-, pentyl ester (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 815588-84-2 CAPLUS

CN Carbamic acid, [5-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-1,4,5,6-tetrahydro-4-oxo-1,3,5-triazin-2-yl]-, hexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 815588-85-3 CAPLUS

CN Carbamic acid, [5-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-1,4,5,6-tetrahydro-4-oxo-1,3,5-triazin-2-yl]-, heptyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 815588-86-4 CAPLUS

CN Carbamic acid, [5-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-1,4,5,6-tetrahydro-4-oxo-1,3,5-triazin-2-yl]-, octyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 815588-87-5 CAPLUS

CN Carbamic acid, [5-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-1,4,5,6-tetrahydro-4-oxo-1,3,5-triazin-2-yl]-, 2-ethylhexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 815588-88-6 CAPLUS

CN Carbamic acid, [5-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-1,4,5,6-tetrahydro-4-oxo-1,3,5-triazin-2-yl]-, nonyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 815588-89-7 CAPLUS

CN Carbamic acid, [5-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-1,4,5,6-tetrahydro-4-oxo-1,3,5-triazin-2-yl]-, decyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 815588-90-0 CAPLUS

CN Carbamic acid, [5-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-1,4,5,6-tetrahydro-4-oxo-1,3,5-triazin-2-yl]-, dodecyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 815588-91-1 CAPLUS

CN Carbamic acid, [5-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-1,4,5,6-tetrahydro-4-oxo-1,3,5-triazin-2-yl]-, hexadecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 815588-92-2 CAPLUS

CN Carbamic acid, [5-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-1,4,5,6-tetrahydro-4-oxo-1,3,5-triazin-2-yl]-, heptadecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/816,161 ALW




IT 114522-16-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(hydrophobic prodrugs of bases, nucleosides, and nucleotides for  
treatment of viral infection and cancer)

RN 114522-16-6 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-  
pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 17 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:921382 CAPLUS  
 DN 142:74789  
 TI Synthesis of unnatural sugar nucleotides and their evaluation as donor  
 substrates in glycosyltransferase-catalyzed reactions  
 AU Khaled, Amira; Ivannikova, Tatiana; Auge, Claudine  
 CS Laboratoire de Chimie Organique Multifonctionnelle, UMR 8614, GDR 2590,  
 Institut de Chimie Moléculaire et des Matériaux d'Orsay (ICMMO),  
 Université Paris-Sud, Orsay, F-91405, Fr.  
 SO Carbohydrate Research (2004), 339(16), 2641-2649  
 CODEN: CRBRAT; ISSN: 0008-6215  
 PB Elsevier B.V.  
 DT Journal  
 LA English  
 OS CASREACT 142:74789  
 IT 813465-91-7P  
 RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic  
 preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant  
 or reagent)  
 (preparation of unnatural sugar nucleotides and their evaluation as donor  
 substrates in glycosyltransferase-catalyzed reactions)  
 RN 813465-91-7 CAPLUS  
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-[5-O-[[[(6-deoxy-β-L-  
 galactopyranosyl)oxy]hydroxyphosphinyl]oxy]hydroxyphosphinyl]-β-D-  
 ribofuranosyl]-, compd. with N,N-diethylethanamine (1:2) (9CI) (CA INDEX  
 NAME)

CM 1

CRN 813465-90-6

CMF C14 H23 N3 O17 P2


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



IT 22432-96-8P 22432-99-1P 813465-99-5P  
 813466-01-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(preparation of unnatural sugar nucleotides and their evaluation as donor substrates in glycosyltransferase-catalyzed reactions)

RN 22432-96-8 CAPLUS

CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-β-D-ribofuranosyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 22432-99-1 CAPLUS

CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 813465-99-5 CAPLUS

CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(5-O-phosphono-β-D-ribofuranosyl)-, diammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● 2 NH<sub>3</sub>

RN 813466-01-2 CAPLUS

10/816,161 ALW


CN 4-Morpholinecarboximidamide, N,N'-dicyclohexyl-, compd. with  
1-[5-O-(hydroxy-4-morpholinylphosphinyl)- $\beta$ -D-ribofuranosyl]-1,3,5-  
triazine-2,4,6(1H,3H,5H)-trione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 813466-00-1

CMF C12 H19 N4 O10 P


Absolute stereochemistry.



CM 2

CRN 4975-73-9

CMF C17 H31 N3 O




RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

L4 ANSWER 18 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:368857 CAPLUS  
DN 140:386000  
TI Compounds, compositions and methods for modulating fat metabolism for  
treatment of metabolic disorders  
IN Gaudriault, Georges; Kilinc, Ahmet; Bousquet, Olivier; Goupil-Lamy, Anne;  
Harosh, Itzik  
PA Obetherapy Biotechnology, Fr.  
SO PCT Int. Appl., 461 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037159	A2	20040506	WO 2003-IL860	20031023
	WO 2004037159	A3	20040715		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003274652	A1	20040513	AU 2003-274652	20031023
PRAI	US 2002-420316P	P	20021023		
	WO 2003-IL860	W	20031023		
OS	MARPAT 140:386000				
IT	114522-16-6 686299-49-0D, stereoisomers				
	686299-50-3D, stereoisomers 686299-60-5D, stereoisomers				
	686299-63-8D, stereoisomers 686299-66-1D, stereoisomers				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(comps., compns. and methods for modulating fat metabolism for treatment of metabolic disorders)				
RN	114522-16-6 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RN 686299-49-0 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-pentofuranosyl-,  
monohydrochloride (9CI) (CA INDEX NAME)


10/816,161 ALW



● HCl


RN 686299-50-3 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-pentofuranosyl- (9CI) (CA INDEX NAME)




RN 686299-60-5 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(5-chloro-5-deoxypentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 686299-63-8 CAPLUS


CN 1,3,5-Triazine-2,4(1H,3H)-dione, 6-amino-3-pentofuranosyl- (9CI) (CA INDEX NAME)



RN 686299-66-1 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxypentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)


10/816,161 ALW



10/816,161 ALW

L4 ANSWER 19 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:348850 CAPLUS  
DN 141:167110  
TI Anticancer agents: tumor cell growth inhibitory activity and binary QSAR analysis  
AU Ren, Steven S.; Lien, Eric J.  
CS Department of Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, 90089-9121, USA  
SO Current Pharmaceutical Design (2004), 10(12), 1399-1415  
CODEN: CPDEFP; ISSN: 1381-6128  
PB Bentham Science Publishers Ltd.  
DT Journal  
LA English  
IT 62402-31-7  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)  
(binary QSAR evaluation of anticancer agents based on tumor cell growth inhibitory activity)  
RN 62402-31-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT




10/816,161 ALW

L4 ANSWER 20 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:290464 CAPLUS  
DN 140:297477  
TI Treatment of viral diseases by 1,3,5-triazine nucleoside and nucleotide  
analogs, and preparation thereof  
IN Daifuku, Richard; Gall, Alexander; Sergueev, Dmitri  
PA Koronis Pharmaceuticals, Incorporated, USA  
SO PCT Int. Appl., 108 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004028454	A2	20040408	WO 2003-US30200	20030924
	WO 2004028454	A3	20041118		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2499036	A1	20040408	CA 2003-2499036	20030924
	AU 2003278904	A1	20040419	AU 2003-278904	20030924
	US 2004127436	A1	20040701	US 2003-670915	20030924
	EP 1545558	A2	20050629	EP 2003-770420	20030924
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2006507255	T	20060302	JP 2004-539890	20030924
PRAI	US 2002-413337P	P	20020924		
	WO 2003-US30200	W	20030924		
OS	MARPAT 140:297477				
IT	114522-16-6P				
	RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(treatment of viral diseases 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)				
RN	114522-16-6 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



IT 676607-98-0P


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(treatment of viral diseases 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

RN 676607-98-0 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-5-O-(1-oxohexadecyl)- $\beta$ -D-erythro-pentofuranosyl]-5,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 114522-18-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(treatment of viral diseases 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

RN 114522-18-8 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\beta$ -D-erythro-pentofuranosyl]-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 114522-19-9P 676607-94-6P 676607-96-8P

RL: SPN (Synthetic preparation); PREP (Preparation)


(treatment of viral diseases 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof)

RN 114522-19-9 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\alpha$ -D-erythro-pentofuranosyl]-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/816,161 ALW



RN 676607-94-6 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-5,6-dihydro-5-methyl-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676607-96-8 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-5,6-dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 21 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:271057 CAPLUS  
DN 141:64376  
TI Structure-based rationalization of antitumor drugs mechanism of action by  
a MIF approach  
AU Cruciani, Gabriele; Benedetti, Paolo; Caltabiano, Gianluigi; Condorelli,  
Daniele F.; Fortuna, Cosimo G.; Musumarra, Giuseppe  
CS Dipartimento di Chimica, Laboratorio di Chemiometria e Chemioinformatica,  
Universita degli Studi di Perugia, Perugia, Italy  
SO European Journal of Medicinal Chemistry (2004), 39(3), 281-289  
CODEN: EJMCA5; ISSN: 0223-5234  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
IT 62488-57-7, 5,6-Dihydro-5-azacytidine  
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological  
study); USES (Uses)  
(structure-based rationalization of antitumor drugs mechanism of action  
by MIF approach)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW


L4 ANSWER 22 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:277528 CAPLUS  
DN 139:149866  
TI Synthesis of N4-alkyl-5-azacytidines and their base-pairing with  
carbamoylguanidines - a contribution to explanation of the mutagenicity of  
2'-deoxy-5-azacytidine  
AU Piskala, Alois; Hanna, Naeem B.; Masojidkova, Milena; Otmar, Miroslav;  
Fiedler, Pavel; Ubik, Karel  
CS Institute of Organic Chemistry and Biochemistry, Academy of Sciences of  
the Czech Republic, Prague, 166 10/6, Czech Rep.  
SO Collection of Czechoslovak Chemical Communications (2003), 68(4), 711-743  
CODEN: CCCCAK; ISSN: 0010-0765  
PB Institute of Organic Chemistry and Biochemistry, Academy of Sciences of  
the Czech Republic  
DT Journal  
LA English  
OS CASREACT 139:149866  
IT 62488-57-7 114522-16-6  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(synthesis of nalkylazacytidines and their basepairing with  
carbamoylguanidines contribution to explanation of mutagenicity of  
deoxyazacytidine)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 114522-16-6 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy- $\beta$ -D-erythro-  
pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 71084-42-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(synthesis of nalkylazacytidines and their basepairing with  
carbamoylguanidines contribution to explanation of mutagenicity of

10/816,161 ALW

deoxyazacytidine)  
RN 71084-42-9 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-[2,3,5-tris-O-(phenylmethyl)- $\beta$ -D-arabinofuranosyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 570410-64-9P 570410-65-0P 570410-75-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of nalkylazacytidines and their basepairing with carbamoylguanidines contribution to explanation of mutagenicity of deoxyazacytidine)  
RN 570410-64-9 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-, compd. with 4-amino-1- $\beta$ -D-ribofuranosyl-1,3,5-triazin-2(1H)-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 62488-57-7  
CMF C8 H14 N4 O5

Absolute stereochemistry.




CM 2

CRN 320-67-2  
CMF C8 H12 N4 O5

Absolute stereochemistry.


10/816,161 ALW



RN 570410-65-0 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-[2,3,5-tris-O-(phenylmethyl)-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 570410-75-2 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6-dihydro-, compd. with 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 114522-16-6

CMF C8 H14 N4 O4

Absolute stereochemistry.




CM 2

CRN 2353-33-5

CMF C8 H12 N4 O4

Absolute stereochemistry.

10/816,161 ALW




RE.CNT 66 . THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/816,161 ALW

L4 ANSWER 23 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:109003 CAPLUS  
DN 139:46601  
TI Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: A statistical analysis of information in the National Cancer Institute database  
AU Bykov, Vladimir J. N.; Issaeva, Natalia; Selivanova, Galina; Wiman, Klas G.  
CS Karolinska Institutet, Department of Oncology-Pathology, Cancer Center Karolinska (CCK), Stockholm, SE-171 76, Swed.  
SO Carcinogenesis (2002), 23(12), 2011-2018  
CODEN: CRNGDP; ISSN: 0143-3334  
PB Oxford University Press  
DT Journal  
LA English  
IT 62488-57-7, 5,6-Dihydro-5-azacytidine  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

L4 ANSWER 24 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2002:964604 CAPLUS  
DN 138:34117  
TI Methods for analyzing nucleic acid methylation and their use in diagnosis  
and treatment of diseases  
IN Shia, Michael A.; Wong, Gordon G.  
PA U.S. Genomics, Inc., USA  
SO PCT Int. Appl., 55 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002101353	A2	20021219	WO 2002-US18178	20020610
	WO 2002101353	A3	20031009		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002318336	A1	20021223	AU 2002-318336	20020610
	US 2002197639	A1	20021226	US 2002-165914	20020610
	EP 1402071	A2	20040331	EP 2002-747887	20020610
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004536596	T	20041209	JP 2003-504066	20020610
PRAI	US 2001-297147P	P	20010608		
	WO 2002-US18178	W	20020610		
IT	62488-57-7, 5,6-Dihydro-5-azacytidine				
	RL: PAC (Pharmacological activity); BIOL (Biological study)				
	(screening for efficacy of; methods for analyzing nucleic acid methylation and their use in diagnosis and treatment of diseases)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-				
	(9CI) (CA INDEX NAME)				

Absolute stereochemistry.




10/816,161 ALW

L4 ANSWER 25 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2002:695764 CAPLUS  
DN 137:210932  
TI Combination therapy for reduction of toxicity of chemotherapeutic agents  
IN Prendergast, Patrick T.  
PA Ire.  
SO PCT Int. Appl., 66 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002069949	A2	20020912	WO 2002-IB632	20020305
	WO 2002069949	A3	20030605		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002169140	A1	20021114	US 2002-91855	20020306
PRAI	IE 2001-209	A	20010306		
IT	62488-57-7, 5,6-Dihydro-5-azacytidine				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(combination therapy for reduction of toxicity of chemotherapeutic agents)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-				
	(9CI) (CA INDEX NAME)				

Absolute stereochemistry.




10/816,161 ALW

L4 ANSWER 26 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2002:521462 CAPLUS  
DN 137:88442  
TI Incensole and furanogermacrene and compounds in treatment for inhibiting  
neoplastic lesions and microorganisms  
IN Shanahan-Pendergast, Elisabeth  
PA Ire.  
SO PCT Int. Appl., 68 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053138	A2	20020711	WO 2002-IE1	20020102
	WO 2002053138	A3	20020919		
	W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG				
	AU 2002219472	A1	20020716	AU 2002-219472	20020102
	EP 1351678	A2	20031015	EP 2002-727007	20020102
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004092583	A1	20040513	US 2004-250535	20040102
PRAI	IE 2001-2	A	20010102		
	WO 2002-IE1	W	20020102		
OS	MARPAT 137:88442				
IT	62488-57-7				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-				
	(9CI) (CA INDEX NAME)				


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 27 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2002:469230 CAPLUS  
DN 138:32948  
TI DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program  
AU Xu, Zhiyuan; Chen, Zhong-Ping; Malapetsa, Areti; Alaoui-Jamall, Moulay; Bergeron, Josee; Monks, Anne; Myers, Timothy G.; Mohr, Gerard; Sausville, Edward A.; Scudiero, Dominic A.; Aloyz, Raquel; Panasci, Lawrence C.  
CS Lady Davis Institute for Medical Research, Sir Mortimer B Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Can.  
SO Anti-Cancer Drugs (2002), 13(5), 511-519  
CODEN: ANTDEV; ISSN: 0959-4973  
PB Lippincott Williams & Wilkins  
DT Journal  
LA English  
IT 62488-57-7, 5,6-Dihydro-5-azacytidine  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(DNA repair protein levels vis-a-vis anticancer drug resistance in human tumor cell lines of National Cancer Institute drug screening program)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

L4 ANSWER 28 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2002:458415 CAPLUS  
DN 138:100377  
TI Identification of active antiviral compounds against a New York isolate of  
West Nile virus  
AU Morrey, John D.; Smee, Donald F.; Sidwell, Robert W.; Tseng, Christopher  
CS Department of Animal, Dairy, and Veterinary Sciences, Institute for  
Antiviral Research, Utah State University, Logan, UT, 84322-4700, USA  
SO Antiviral Research (2002), 55(1), 107-116  
CODEN: ARSRDR; ISSN: 0166-3542  
PB Elsevier Science B.V.  
DT Journal  
LA English  
IT 62488-57-7  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(identification of active antiviral compds. against a New York isolate  
of West Nile virus)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

L4 ANSWER 29 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2001:300885 CAPLUS  
DN 134:306207  
TI Cloning of TMS1 gene and its use in the diagnosis and treatment of breast cancer  
IN Vertino, Paula M.  
PA Emory University, USA  
SO PCT Int. Appl., 124 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001029235	A2	20010426	WO 2000-US28747	20001018
	WO 2001029235	A3	20020516		
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2386476	A1	20010426	CA 2000-2386476	20001018
	EP 1224303	A2	20020724	EP 2000-973614	20001018
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 6911306	B1	20050628	US 2000-691763	20001018
	AU 785115	B2	20060921	AU 2001-12110	20001018
	US 2006040284	A1	20060223	US 2005-120665	20050503
PRAI	US 1999-159975P	P	19991018		
	US 2000-691763	A3	20001018		
	WO 2000-US28747	W	20001018		
IT	62488-57-7, 5,6-Dihydro-5-azacytidine				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)				
	(inhibitors of methytransferase; cloning of TMS1 gene and its use in the diagnosis and treatment of breast cancer)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-				
	(9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L4 ANSWER 30 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2000:597834 CAPLUS  
 DN 133:322096  
 TI Stereocontrolled Syntheses of Deoxyribonucleosides via Photo-Induced  
 Electron-Transfer Deoxygenation of Benzoyl-Protected Ribo- and  
 Arabinonucleosides  
 AU Wang, Zhiwei; Prudhomme, Daniel R.; Buck, Jason R.; Park, Minnie; Rizzo,  
 Carmelo J.  
 CS Department of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA  
 SO Journal of Organic Chemistry (2000), 65(19), 5969-5985  
 CODEN: JOCEAH; ISSN: 0022-3263  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 133:322096  
 IT 303040-78-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (stereocontrolled syntheses of deoxyribonucleosides via photo-induced  
 electron-transfer deoxygenation of benzoyl-protected ribo- and  
 arabino-nucleosides)  
 RN 303040-78-0 CAPLUS  
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-[3,5-di-O-benzoyl-2-O-[3-  
 (trifluoromethyl)benzoyl]- $\beta$ -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 303040-85-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (stereocontrolled syntheses of deoxyribonucleosides via photo-induced  
 electron-transfer deoxygenation of benzoyl-protected ribo- and  
 arabino-nucleosides)  
 RN 303040-85-9 CAPLUS  
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(3,5-di-O-benzoyl-2-deoxy- $\beta$ -  
 D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



10/816,161 ALW



RE.CNT 109 THERE ARE 109 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

L4 ANSWER 31 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:589895 CAPLUS

DN 133:198574

TI In vivo agents comprising antitumor cationic drugs, peptides, and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles

IN Ranney, David F.

PA Access Pharmaceuticals, Inc., USA

SO U.S., 109 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 6106866	A	20000822	US 1995-509338	19950731
PRAI	US 1995-509338		19950731		
IT	62488-57-7				


RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(antitumor cationic drugs, peptides, and metal chelators with acidic saccharides and glycosaminoglycans, having site-selective localization and uptake mechanism)

RN 62488-57-7 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 122 THERE ARE 122 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2000:488523 CAPLUS  
DN 133:217357  
TI Characterization of anticancer agents by their growth inhibitory activity  
and relationships to mechanism of action and structure  
AU Keskin, Ozlem; Bahar, Ivet; Jernigan, Robert L.; Beutler, John A.;  
Shoemaker, Robert H.; Sausville, Edward A.; Covell, David G.  
CS Chemical Engineering Department and Polymer Research Center, TUBITAK  
Advanced Polymeric Materials Research Center, Bogazici University,  
Istanbul, 80815, Turk.  
SO Anti-Cancer Drug Design (2000), 15(2), 79-98  
CODEN: ACDDEA; ISSN: 0266-9536  
PB Oxford University Press  
DT Journal  
LA English  
IT 62488-57-7, 5,6-Dihydro-5-azacytidine  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); BIOL (Biological study)  
(characterization of anticancer agents by growth inhibitory activity  
and relationships to mechanism of action and structure)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

L4 ANSWER 33 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2000:475560 CAPLUS  
DN 133:109949  
TI Pharmaceutical compositions for treatment of diseased tissues  
IN Lee, Clarence C.; Lee, Feng-Min  
PA USA  
SO PCT Int. Appl., 26 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000040269	A2	20000713	WO 2000-US191	20000105
	WO 2000040269	A3	20001130		
	W: AU, CA, CN, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRAI US 1999-114906P P 19990105


IT 62488-57-7, DHAC

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (DHAC; pharmaceutical compns. for treatment of diseased tissues)

RN 62488-57-7 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 34 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2000:422410 CAPLUS  
DN 133:129502  
TI 1H NMR conformational study of antiherpetic C5-substituted  
2'-deoxyuridines: insight into the nature of structure-activity  
relationships  
AU Poznanski, Jaroslaw; Felczak, Krzysztof; Kulikowski, Tadeusz; Remin,  
Mieczyslaw  
CS Institute of Biochemistry and Biophysics, Polish Academy of Sciences,  
Warsaw, 02-106, Pol.  
SO Biochemical and Biophysical Research Communications (2000), 272(1), 64-74  
CODEN: BBRC9; ISSN: 0006-291X  
PB Academic Press  
DT Journal  
LA English  
IT 70165-41-2  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(structure-activity relationship of antiherpetic C5-substituted  
2'-deoxyuridines)  
RN 70165-41-2 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(2-deoxy- $\beta$ -D-erythro-  
pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2000:277883 CAPLUS  
 DN 132:318052  
 TI Modulation of gene expression by combination therapy with antisense  
 oligonucleotide and gene product protein effector  
 IN Besterman, Jeffrey M.; Macleod, Alan Robert; Siders, William M.  
 PA Methylgene, Inc., Can.  
 SO PCT Int. Appl., 99 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000023112	A1	20000427	WO 1999-US24278	19991019
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2347003	A1	20000427	CA 1999-2347003	19991019
	AU 9965194	A1	20000508	AU 1999-65194	19991019
	AU 766084	B2	20031009		
	EP 1123111	A1	20010816	EP 1999-953211	19991019
	EP 1123111	B1	20040915		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002528391	T	20020903	JP 2000-576885	19991019
	EP 1243289	A2	20020925	EP 2002-14370	19991019
	EP 1243289	A3	20040317		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	EP 1243290	A2	20020925	EP 2002-14371	19991019
	EP 1243290	A3	20040317		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	AT 275956	T	20041015	AT 1999-953211	19991019
	ES 2228119	T3	20050401	ES 1999-953211	19991019
	US 6953783	B1	20051011	US 1999-420692	19991019
	US 2003096777	A1	20030522	US 2002-145493	20020514
	AU 2004200032	A1	20040129	AU 2004-200032	20040106
PRAI	US 1998-104804P	P	19981019		
	AU 1999-65194	A3	19991019		
	EP 1999-953211	A3	19991019		
	US 1999-420692	A3	19991019		
	WO 1999-US24278	W	19991019		
IT	62488-57-7, 5,6-Dihydro-5-azacytidine				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(antisense oligonucleotide and gene product protein effector for gene expression modulation)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-(9CI) (CA INDEX NAME)				

Absolute stereochemistry.

10/816,161 ALW



RE.CNT 1      THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

L4 ANSWER 36 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2000:227537 CAPLUS  
DN 132:262172  
TI Use of neoangiogenesis markers for diagnosis and treatment of tumors  
IN Krause, Werner; Muschick, Peter  
PA Schering Aktiengesellschaft, Germany  
SO PCT Int. Appl., 27 pp.  
CODEN: PIXXD2


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018439	A2	20000406	WO 1999-EP7198	19990929
	WO 2000018439	A3	20000914		
	W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, ES, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 19845798	A1	20000413	DE 1998-19845798	19980929
PRAI	DE 1998-19845798	A	19980929		
IT	62488-57-7D, conjugates with angiogenesis markers				
	RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)				
	(use of neoangiogenesis markers for diagnosis and treatment of tumors)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-(9CI) (CA INDEX NAME)				


Absolute stereochemistry.





L4 ANSWER 37 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2000:192947 CAPLUS  
DN 133:100386  
TI A gene expression database for the molecular pharmacology of cancer  
AU Scherf, Uwe; Ross, Douglas T.; Waltham, Mark; Smith, Lawrence H.; Lee, Jae K.; Tanabe, Lorraine; Kohn, Kurt W.; Reinhold, William C.; Myers, Timothy G.; Andrews, Darren T.; Scudiero, Dominic A.; Eisen, Michael B.; Sausville, Edward A.; Pommier, Yves; Botstein, David; Brown, Patrick O.; Weinstein, John N.  
CS Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA  
SO Nature Genetics (2000), 24(3), 236-244  
CODEN: NGENEC; ISSN: 1061-4036  
PB Nature America  
DT Journal  
LA English  
IT 62488-57-7, 5-6-Dihydro-5-azacytidine  
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(human cancer cell line gene expression database for the mol. pharmacol. of cancer)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW


L4 ANSWER 38 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1999:684980 CAPLUS  
DN 132:46092  
TI Peroxynitrite reaction products of 3',5'-di-O-acetyl-8-oxo-7,8-dihydro-2'-deoxyguanosine  
AU Niles, Jacquin C.; Burney, Samar; Singh, Sukhjeet P.; Wishnok, John S.; Tannenbaum, Steven R.  
CS Division of Bioengineering and Environmental Health, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA  
SO Proceedings of the National Academy of Sciences of the United States of America (1999), 96(21), 11729-11734  
CODEN: PNASA6; ISSN: 0027-8424  
PB National Academy of Sciences  
DT Journal  
LA English  
IT 91990-91-9 252742-98-6  
RL: ADV (Adverse effect, including toxicity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)  
(peroxynitrite reaction products of 3',5'-di-O-acetyl-8-oxo-7,8-dihydro-2'-deoxyguanosine in relation to DNA damage)  
RN 91990-91-9 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(3,5-di-O-acetyl-2-deoxy- $\beta$ -D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252742-98-6 CAPLUS  
CN 1,3,5-Triazine-1(2H)-carboximidamide, 3-(3,5-di-O-acetyl-2-deoxy- $\beta$ -D-erythro-pentofuranosyl)tetrahydro-2,4,6-trioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

L4 ANSWER 39 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1999:396073 CAPLUS  
DN 131:208754  
TI 5,6-dihydro-5'-azacytidine (DHAC) affects estrogen sensitivity in  
estrogen-refractory human breast carcinoma cell lines  
AU Izbicka, Elzbieta; Davidson, Karen K.; Lawrence, Richard A.; Macdonald,  
John R.; Von Hoff, Daniel D.  
CS Cancer Therapy and Research Center, The Nordan Colon Cancer Laboratory,  
Institute for Drug Development, San Antonio, TX, 78229, USA  
SO Anticancer Research (1999), 19(2A), 1293-1298  
CODEN: ANTRD4; ISSN: 0250-7005  
PB International Institute of Anticancer Research  
DT Journal  
LA English  
IT 62488-57-7, 5,6-Dihydro-5-azacytidine  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
(Uses)  
(DHAC affects estrogen sensitivity in estrogen-refractory human breast  
carcinoma cell lines)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

L4 ANSWER 40 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1999:396072 CAPLUS  
DN 131:223166  
TI 5,6 dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in  
androgen-insensitive prostate cancer cells  
AU Izbicka, Elzbieta; Macdonald, John R.; Davidson, Karen; Lawrence, Richard  
A.; Gomez, Lionel; Von Hoff, Daniel D.  
CS Cancer Therapy and Research Center, Institute for Drug Development, San  
Antonio, TX, 78229, USA  
SO Anticancer Research (1999), 19(2A), 1285-1291  
CODEN: ANTRD4; ISSN: 0250-7005  
PB International Institute of Anticancer Research  
DT Journal  
LA English  
IT 62488-57-7  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
(Uses)  
(DHAC restores androgen responsiveness in androgen-insensitive prostate  
cancer cells)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 41 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1999:395230 CAPLUS  
 DN 131:228946  
 TI Synthesis and Biochemical Properties of Cyanuric Acid Nucleoside-Containing DNA Oligomers  
 AU Gasparutto, Didier; Da Cruz, Sandrine; Bourdat, Anne-Gaeelle; Jaquinod, Michel; Cadet, Jean  
 CS Laboratoire des Lesions des Acides Nucleiques Service de Chimie Inorganique et Biologique Departement de Recherche Fondamentale sur la Matiere Condensee, CEA-Grenoble, Grenoble, F-38054, Fr.  
 SO Chemical Research in Toxicology (1999), 12(7), 630-638  
 CODEN: CRTOEC; ISSN: 0893-228X  
 PB American Chemical Society  
 DT Journal  
 LA English  
 IT 243646-88-0P  
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)  
 (synthesis and biochem. properties of cyanuric acid nucleoside-containing DNA oligomers)  
 RN 243646-88-0 CAPLUS  
 CN Thymidine, thymidyl- (3'→5')-2'-deoxy-5,6-dihydro-6-oxo-5-azauridyl- (3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 243646-86-8P  
 RL: BYP (Byproduct); PREP (Preparation)  
 (synthesis and biochem. properties of cyanuric acid nucleoside-containing DNA oligomers)  
 RN 243646-86-8 CAPLUS  
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-2-deoxy-α-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 70165-41-2P 243646-84-6P 243646-85-7P  
243646-87-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(synthesis and biochem. properties of cyanuric acid nucleoside-containing  
DNA oligomers)

RN 70165-41-2 CAPLUS

CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(2-deoxy-β-D-erythro-  
pentofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 243646-84-6 CAPLUS

CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(2-deoxy-α-D-erythro-  
pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 243646-85-7 CAPLUS

CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-[5-O-[[bis(4-  
methoxyphenyl)phenylmethyl]]-2-deoxy-β-D-erythro-pentofuranosyl]-  
(9CI) (CA INDEX NAME)

10/816,161 ALW


Absolute stereochemistry.



RN 243646-87-9 CAPLUS

CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-2-deoxy- $\beta$ -D-erythro-pentofuranosyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 42 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1999:313329 CAPLUS  
 DN 131:180989  
 TI DNA damage in deoxynucleosides and oligonucleotides treated with  
 peroxynitrite  
 AU Burney, Samar; Niles, Jacquin C.; Dedon, Peter C.; Tannenbaum, Steven R.  
 CS Department of Chemistry and Division of Bioengineering and Environmental  
 Health, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA  
 SO Chemical Research in Toxicology (1999), 12(6), 513-520  
 CODEN: CRTOEC; ISSN: 0893-228X  
 PB American Chemical Society  
 DT Journal  
 LA English  
 IT 70165-41-2 174904-71-3  
 RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological  
 study); RACT (Reactant or reagent)  
 (peroxynitrite-induced oxidation of oxodG)  
 RN 70165-41-2 CAPLUS  
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(2-deoxy-β-D-erythro-  
 pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174904-71-3 CAPLUS  
 CN 1,3,5-Triazine-1(2H)-carboximidamide, 3-(2-deoxy-β-D-erythro-  
 pentofuranosyl)tetrahydro-2,4,6-trioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/816,161 ALW

L4 ANSWER 43 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1998:292263 CAPLUS  
DN 129:23072  
TI Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma a phase II study by the cancer and leukemia group B  
AU Samuels, Brian L.; Herndon, James E., II; Harmon, David C.; Carey, Robert; Aisner, Joseph; Corson, Joseph M.; Suzuki, Yasunosuke; Green, Mark R.; Vogelzang, Nicholas J.  
CS Lutheran General Hospital, Park Ridge, IL, USA  
SO Cancer (New York) (1998), 82(8), 1578-1584  
CODEN: CANCAR; ISSN: 0008-543X  
PB John Wiley & Sons, Inc.  
DT Journal  
LA English  
IT 62488-57-7  
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(dihydro-5-azacytidine/cisplatin treatment of malignant mesothelioma in humans)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 44 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1998:290462 CAPLUS  
 DN 128:321852  
 TI Synthesis of some 6-substituted 5-azacytidines  
 AU Hanna, Naeem B.; Masojdikova, Milena; Fiedler, Pavel; Piskala, Alois  
 CS Institute of Organic Chemistry and Biochemistry, Academy of Sciences of  
 the Czech Republic, Prague, 166 10, Czech Rep.  
 SO Collection of Czechoslovak Chemical Communications (1998), 63(2), 222-230  
 CODEN: CCCCAK; ISSN: 0010-0765  
 PB Institute of Organic Chemistry and Biochemistry, Academy of Sciences of  
 the Czech Republic  
 DT Journal  
 LA English  
 IT 207116-69-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
 study); PREP (Preparation)  
 (preparation of some 6-substituted azacytidines)  
 RN 207116-69-6 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 6-amino-4-phenyl-1- $\beta$ -D-ribofuranosyl- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 207116-67-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of some 6-substituted azacytidines)  
 RN 207116-67-4 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 6-amino-4-phenyl-1-(2,3,5-tri-O-benzoyl- $\beta$ -D-  
 ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

L4 ANSWER 45 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1998:87620 CAPLUS  
 DN 128:123806  
 TI Use of 5,6-dihydro-5-azacytidine in the treatment of prostate cancer  
 IN Von Hoff, Daniel D.; Izbicka, Elzbieta  
 PA Ilex Oncology, Inc., USA  
 SO PCT Int. Appl., 34 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9803183	A1	19980129	WO 1997-US13102	19970722
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9740461	A	19980210	AU 1997-40461	19970722
PRAI	US 1996-22042P	P	19960722		
	WO 1997-US13102	W	19970722		
IT	62488-57-7, 5,6-Dihydro-5-azacytidine				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(dihydroazacytidine, alone or in combination, for prostate cancer treatment)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-(9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/816,161 ALW

L4 ANSWER 46 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1997:368731 CAPLUS  
DN 127:60299  
TI Dihydro-5-azacytidine in malignant mesothelioma: a phase II trial  
demonstrating activity accompanied by cardiac toxicity  
AU Vogelzang, Nicholas J.; Herndon, James E.; Cirrincione, Constance; Harmon,  
David C.; Antman, Karen H.; Corson, Joseph M.; Suzuki, Yasunosuke; Citron,  
Marc L.; Green, Mark R.  
CS Section of Hematology/Oncology, University of Chicago Medical Center,  
Chicago, IL, 60637-1470, USA  
SO Cancer (New York) (1997), 79(11), 2237-2242  
CODEN: CANCAR; ISSN: 0008-543X  
PB Wiley  
DT Journal  
LA English  
IT 62488-57-7  
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or  
effector, except adverse); BSU (Biological study, unclassified); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(dihydro-5-azacytidine in malignant mesothelioma dealing with a phase  
II trial demonstrating activity accompanied by cardiac toxicity in  
humans)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 47 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1997:187821 CAPLUS  
 DN 126:293552  
 TI 6-Methyl-5-azacytidine synthesis, conformational properties, and biological activity. A comparison of molecular conformation with 5-azacytidine  
 AU Hanna, Naeem B.; Zajicek, Jaroslav; Piskala, Alois  
 CS Inst. Organic Chem. Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Rep.  
 SO Nucleosides & Nucleotides (1997), 16(1 & 2), 129-144  
 CODEN: NUNUD5; ISSN: 0732-8311  
 PB Dekker  
 DT Journal  
 LA English  
 IT 189129-04-2P 189129-06-4P 189129-07-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (synthesis, conformation, and biol. activity of 6-methyl-5-azacytidine)  
 RN 189129-04-2 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 6-amino-4-methyl-1-(2,3,5-tri-O-benzoyl- $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 189129-06-4 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 6-amino-4-methyl-1- $\beta$ -D-ribofuranosyl- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 189129-07-5 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 6-amino-1-(5-O-benzoyl- $\beta$ -D-ribofuranosyl)-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

10/816,161 ALW



10/816,161 ALW


L4 ANSWER 48 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1996:529503 CAPLUS  
DN 125:177401  
TI Complexes of dermatan sulfate and drugs with improved pharmacokinetics  
IN Ranney, David F.  
PA Access Pharmaceuticals, Inc., USA  
SO PCT Int. Appl., 227 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9619242	A1	19960627	WO 1994-US14776	19941222
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2208566	A1	19960627	CA 1994-2208566	19941222
	AU 9515537	A	19960710	AU 1995-15537	19941222
	AU 709008	B2	19990819		
	EP 794796	A1	19970917	EP 1995-907242	19941222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10510831	T	19981020	JP 1994-519745	19941222
PRAI	WO 1994-US14776		19941222		
IT	62488-57-7DP, reaction products with glycosaminoglycans				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(complexes of dermatan sulfate and drugs with improved pharmacokinetics)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-(9CI) (CA INDEX NAME)				


Absolute stereochemistry.






L4 ANSWER 49 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1996:92211 CAPLUS  
 DN 124:261575  
 TI Photosensitized Reaction of 8-Oxo-7,8-dihydro-2'-deoxyguanosine:  
 Identification of 1-(2-Deoxy- $\beta$ -D-erythro-pentofuranosyl) cyanuric Acid  
 as the Major Singlet Oxygen Oxidation Product  
 AU Raoul, Sebastien; Cadet, Jean  
 CS Departement de Recherche Fondamentale sur la Matiere Condensee, CEA,  
 Grenoble, F-38054, Fr.  
 SO Journal of the American Chemical Society (1996), 118(8), 1892-8  
 CODEN: JACSAT; ISSN: 0002-7863  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 124:261575  
 IT 174904-71-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (photochem. singlet oxygen oxidation of oxodihydrodeoxyguanosine)  
 RN 174904-71-3 CAPLUS  
 CN 1,3,5-Triazine-1(2H)-carboximidamide, 3-(2-deoxy- $\beta$ -D-erythro-  
 pentofuranosyl)tetrahydro-2,4,6-trioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 70165-41-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (photochem. singlet oxygen oxidation of oxodihydrodeoxyguanosine)  
 RN 70165-41-2 CAPLUS  
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(2-deoxy- $\beta$ -D-erythro-  
 pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 50 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1995:1002298 CAPLUS  
 DN 124:176774  
 TI Polarographic reduction and potential carcinogenicity of substituted  
 1,3,5-triazine nucleosides  
 AU Novotny, Ladislav; Vachalkova, Anna; Piskala, Alois  
 CS Cancer Res. Inst., Slovak Acad. Sci., Bratislava, 812 32, Swed.  
 SO Collection of Czechoslovak Chemical Communications (1995), 60(9), 1469-75  
 CODEN: CCCCAK; ISSN: 0010-0765  
 PB Institute of Organic Chemistry and Biochemistry, Academy of Sciences of  
 the Czech Republic  
 DT Journal  
 LA English  
 IT 65370-91-4 105331-00-8, 6-Amino-5-azacytidine  
 173949-66-1  
 RL: ADV (Adverse effect, including toxicity); RCT (Reactant); BIOL  
 (Biological study); RACT (Reactant or reagent)  
 (polarog. reduction and potential carcinogenicity of triazine nucleosides)  
 RN 65370-91-4 CAPLUS  
 CN 1,3,5-Triazine-2,4(1H,3H)-dione, 6-amino-3- $\beta$ -D-ribofuranosyl- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 105331-00-8 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 4,6-diamino-1- $\beta$ -D-ribofuranosyl- (9CI) (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 173949-66-1 CAPLUS  
 CN 1,3,5-Triazine-2,4(1H,3H)-dione, 6-amino-1- $\beta$ -D-ribofuranosyl- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.


10/816,161 ALW



10/816,161 ALW

L4 ANSWER 51 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1995:885986 CAPLUS  
DN 124:23823  
TI Influence of ribosyl-DHT and DHT on the replication of PVX and on the  
activity of the PVX-induced RNA-dependent RNA polymerase  
AU Schuster, G.; Schulze, S.; Piskala, A.  
CS Fak. Biowiss., Pharmazie Psychlogie, Univ. Leipzig, Leipzig, D-04103,  
Germany  
SO Zeitschrift fuer Pflanzenkrankheiten und Pflanzenschutz (1995), 102(2),  
215-19  
CODEN: ZPFPA; ISSN: 0340-8159  
PB Ulmer  
DT Journal  
LA German  
IT 114522-22-4  
RL: AGR (Agricultural use); BAC (Biological activity or effector, except  
adverse); BSU (Biological study, unclassified); BIOL (Biological study);  
USES (Uses)  
(influence of ribosyl-DHT and DHT on the replication of PVX and on the  
activity of the PVX-induced RNA-dependent RNA polymerase)  
RN 114522-22-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1-β-D-ribofuranosyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW


L4 ANSWER 52 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1995:707279 CAPLUS  
DN 123:132224  
TI Micronuclei induced by modulators of methylation: analogs of 5-azacytidine  
AU Stopper, Helga; Koerber, Carsten; Gibis, Petra; Spencer, Diane L.;  
Caspary, William J.  
CS Inst. Pharmacology and Toxicology, Univ. Wuerzburg, Wuerzburg, 97078,  
Germany  
SO Carcinogenesis (1995), 16(7), 1647-50  
CODEN: CRNGDP; ISSN: 0143-3334  
PB Oxford University Press  
DT Journal  
LA English  
IT 62488-57-7, 5,6-Dihydro-5-azacytidine  
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(micronuclei induced by analogs of azacytidine and role of DNA  
methylation)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 53 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1995:550185 CAPLUS  
 DN 123:25321  
 TI Biochemical pharmacology and DNA methylation studies of arabinosyl  
 5-azacytidine and 5,6-dihydro-5-azacytidine in two human leukemia cell  
 lines PER-145 and PER-163  
 AU Kees, Ursula R.; Avramis, Vassilios I.  
 CS Inst. Child Health Res., Princess Margaret Hosp., West Perth, Australia  
 SO Anti-Cancer Drugs (1995), 6(2), 303-10  
 CODEN: ANTDEV; ISSN: 0959-4973  
 PB Rapid Science Publishers  
 DT Journal  
 LA English  
 IT 115723-52-9, DHACTP 122277-00-3, DHAdCTP  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); MFM (Metabolic formation); BIOL (Biological study);  
 FORM (Formation, nonpreparative)  
 (biochem. pharmacol. and DNA methylation studies of arabinosyl  
 azacytidine and dihydroazacytidine in sensitive and resistant human  
 leukemia cells)  
 RN 115723-52-9 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-[5-O-  
 [hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]- $\beta$ -D-  
 ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 122277-00-3 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-5-O-  
 [hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]- $\beta$ -D-erythro-  
 pentofuranosyl]-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 62488-57-7, DHAC  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)  
 (biochem. pharmacol. and DNA methylation studies of arabinosyl


10/816,161 ALW

azacytidine and dihydroazacytidine in sensitive and resistant human leukemia cells)

RN 62488-57-7 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 54 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1994:570013 CAPLUS  
 DN 121:170013  
 TI Polarographic reduction and potential carcinogenicity of synthetic  
 1,3,5-triazine bases and nucleosides  
 AU Novotny, Ladislav; Vachalkova, Anna; Piskala, Alois  
 CS Cancer Research Institute, Slovak Academy Sciences, Bratislava, 812 32,  
 Slovakia  
 SO Collection of Czechoslovak Chemical Communications (1994), 59(7), 1691-8  
 CODEN: CCCCAK; ISSN: 0010-0765  
 DT Journal  
 LA English  
 IT 62488-57-7, 5,6-Dihydro-5-azacytidine 114522-16-6,  
 2'-Deoxy-5,6-Dihydro-5-azacytidine 114522-22-4  
 RL: PRP (Properties)  
 (polarog. reduction potential of, carcinogenicity in relation to)  
 RN 62488-57-7 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 114522-16-6 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy- $\beta$ -D-erythro-  
 pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 114522-22-4 CAPLUS  
 CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1- $\beta$ -D-ribofuranosyl- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



10/816,161 ALW



10/816,161 ALW

L4 ANSWER 55 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1993:575369 CAPLUS  
DN 119:175369  
TI Formation of triple helix complexes of single stranded nucleic acids using  
oligonucleotides  
IN Ts'O, Paul On Pong; Adams, Thomas Henry; Arnold, Lyle J., Jr.  
PA Johns Hopkins University, USA; Genta Inc.  
SO PCT Int. Appl., 98 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9307295	A1	19930415	WO 1992-US8458	19921005
	W: AU, CA, FI, JP, KR, NO, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	AU 9227852	A	19930503	AU 1992-27852	19921005
	JP 07501936	T	19950302	JP 1992-507113	19921005
	EP 650526	A1	19950503	EP 1992-921942	19921005
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
	US 5834185	A	19981110	US 1994-342647	19941121
	AU 9724881	A	19970904	AU 1997-24881	19970613
PRAI	US 1991-772081	A	19911007		
	US 1986-924234	B2	19861028		
	US 1989-368027	B2	19890619		
	WO 1992-US8458	A	19921005		
	US 1992-978937	B1	19921118		
	US 1994-194731	B1	19940210		

IT 114522-16-6


RL: USES (Uses)

(oligonucleotide containing, diagnosis or inhibition of nucleic acid  
.function by triple helix formation with)

RN 114522-16-6 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy- $\beta$ -D-erythro-  
pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 56 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1992:612897 CAPLUS

DN 117:212897

TI Method for the preparation of anomers of 4,6-diamino-1- $\alpha$ - and - $\beta$ -D-arabinofuranosyl-1,3,5-triazin-2(1H)-ones

IN Alexander, Petr; Vesely, Jiri; Piskala, Alois

PA Czech.

SO Czech., 5 pp.


CODEN: CZXXA9

DT Patent


LA Czech

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 273854	B1	19910411	CS 1989-160	19890110
PRAI	CS 1989-160		19890110		
OS	MARPAT 117:212897				
IT	143994-54-1P 143994-55-2P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and debenzoylation of)				
RN	143994-54-1 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4,6-diamino-1-[2,3,5-tris-O-(phenylmethyl)- $\beta$ -D-arabinofuranosyl]- (9CI) (CA INDEX NAME)				



RN 143994-55-2 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4,6-diamino-1-[2,3,5-tris-O-(phenylmethyl)- $\alpha$ -D-arabinofuranosyl]- (9CI) (CA INDEX NAME)


IT 143994-52-9P 143994-53-0P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, method for)

RN 143994-52-9 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4,6-diamino-1- $\beta$ -D-arabinofuranosyl- (9CI) (CA INDEX NAME)

10/816,161 ALW



RN 143994-53-0 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4,6-diamino-1- $\alpha$ -D-arabinofuranosyl- (9CI)  
(CA INDEX NAME)




10/816,161 ALW

L4 ANSWER 57 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1992:449157 CAPLUS  
DN 117:49157  
TI Preparation of brain-targeted acyloxymethylphosphonate prodrugs  
IN Bodor, Nicholas S.  
PA USA  
SO PCT Int. Appl., 179 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9200988	A1	19920123	WO 1991-US4824	19910712
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MN, MW, NL, NO, PL, RO, SD, SE, SU				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	US 5177064	A	19930105	US 1990-553548	19900713
	CA 2087194	A1	19920114	CA 1991-2087194	19910712
	AU 9183000	A	19920204	AU 1991-83000	19910712
	AU 649466	B2	19940526		
	EP 539493	A1	19930505	EP 1991-913701	19910712
	EP 539493	B1	19970326		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05509313	T	19931222	JP 1991-513064	19910712
	AT 150759	T	19970415	AT 1991-913701	19910712
	US 5413996	A	19950509	US 1992-962504	19921016
	US 5618803	A	19970408	US 1994-340896	19941115
PRAI	US 1990-553548	A	19900713		
	WO 1991-US4824	A	19910712		
	US 1992-962504	A3	19921016		
OS	MARPAT 117:49157				
IT	114522-22-4DP, acyloxymethylphosphonate derivative				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of, as brain-targeted prodrug)				
RN	114522-22-4 CAPLUS				
CN	1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1- $\beta$ -D-ribofuranosyl- (9CI)				
	(CA INDEX NAME)				

Absolute stereochemistry.




10/816,161 ALW

L4 ANSWER 58 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1992:99301 CAPLUS  
DN 116:99301  
TI Maleic anhydride copolymers as antidotes for the cytotoxicity of neoplasm inhibitors  
IN Bach, Ardalan; Shanahan, William R., Jr.  
PA G.D. Searle and Co., USA  
SO Eur. Pat. Appl., 27 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 393575	A1	19901024	EP 1990-107246	19900417
	EP 393575	B1	19940316		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2014732	A1	19901017	CA 1990-2014732	19900417
	JP 02292227	A	19901203	JP 1990-101530	19900417
	AT 102838	T	19940415	AT 1990-107246	19900417
	ES 2062155	T3	19941216	ES 1990-107246	19900417
PRAI	US 1989-339503	A	19890417		
	EP 1990-107246	A	19900417		
OS	MARPAT 116:99301				
IT	62488-57-7, NSC 26480				
	RL: PRP (Properties)				
	(cytotoxicity of, maleic anhydride copolymer antidote for)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-				
	(9CI) (CA INDEX NAME)				

Absolute stereochemistry.




10/816,161 ALW

L4 ANSWER 59 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1991:400778 CAPLUS  
DN 115:778  
TI Covalently-linked complexes and methods for enhanced cytotoxicity and imaging  
IN Anderson, David C.; Morgan, A. Charles; Abrams, Paul G.; Nichols, Everett J.; Fritzberg, Alan R.  
PA NeoRx Corp., USA  
SO Eur. Pat. Appl., 23 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	---	-----	-----
PI	EP 359347	A2	19900321	EP 1989-250014	19890814
	EP 359347	A3	19900418		
	EP 359347	B1	19921223		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5135736	A	19920804	US 1988-232337	19880815
	US 5169933	A	19921208	US 1989-390241	19890807
	CA 1334513	C	19950221	CA 1989-608198	19890811
	JP 02124833	A	19900514	JP 1989-209992	19890814
	AT 83669	T	19930115	AT 1989-250014	19890814
PRAI	US 1988-232337	A	19880815		
	EP 1989-250014	A	19890814		
IT	62488-57-7D, conjugates with targeting protein and target cell interaction enhancer				
	RL: BIOL (Biological study)				
	(cell targeting with, for enhanced cytotoxicity and imaging)				
RN	62488-57-7 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-				
	(9CI) (CA INDEX NAME)				

Absolute stereochemistry.



10/816,161 ALW


L4 ANSWER 60 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1990:631939 CAPLUS  
DN 113:231939  
TI Preparation of 2'-deoxy-5,6-dihydro-5-azacytidine as a new  
2'-deoxycytidine analog  
IN Piskala, Alois; Cesnekova, Barbara; Vesely, Jiri  
PA Czech.  
SO Czech., 5 pp.  
CODEN: CZXXA9  
DT Patent  
LA Czech  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 264454	B1	19890814	CS 1987-6304	19870828
PRAI	CS 1987-6304		19870828		
OS	MARPAT 113:231939				
IT	130518-66-0P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and deprotection of)				
RN	130518-66-0 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- β-D-erythro-pentofuranosyl]-3,6-dihydro-, acetate (9CI) (CA INDEX NAME)				

CM 1


CRN 114522-18-8  
CMF C24 H26 N4 O6

Absolute stereochemistry.



CM . 2

CRN 64-19-7  
CMF C2 H4 O2






10/816,161 ALW

IT 130530-59-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 130530-59-5 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-  
pentofuranosyl)-3,6-dihydro-, acetate (9CI) (CA INDEX NAME)

CM 1


CRN 114522-16-6  
CMF C8 H14 N4 O4

Absolute stereochemistry.




CM 2

CRN 64-19-7  
CMF C2 H4 O2



IT 114522-16-6P, 2'-Deoxy-5,6-dihydro-5-azacytidine  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, by reduction of deoxyazacytidine)  
RN 114522-16-6 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-  
pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 114522-18-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reduction of, by zinc and acetic acid)  
RN 114522-18-8 CAPLUS

10/816,161 ALW

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\beta$ -D-erythro-pentofuranosyl]-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/816,161 ALW

L4 ANSWER 61 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1990:612583 CAPLUS  
DN 113:212583  
TI Preparation of 5,6-dihydro-5-azauridine as a new uridine analog  
IN Piskala, Alois; Cesnekova, Barbara; Vesely, Jiri  
PA Czech.  
SO Czech., 4 pp.  
CODEN: CZXXA9  
DT Patent  
LA Czech  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 264455	B1	19890814	CS 1987-6305	19870828
PRAI	CS 1987-6305		19870828		
OS	CASREACT 113:212583; MARPAT 113:212583				
IT	130518-67-1P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and deprotection of)				
RN	130518-67-1 CAPLUS				
CN	1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1-(2,3,5-tri-O-benzoyl- $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



IT 114522-22-4P  
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, by reduction of (benzoyl)azauridine)  
RN 114522-22-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1- $\beta$ -D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/816,161 ALW


L4 ANSWER 62 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1990:612582 CAPLUS  
DN 113:212582  
TI Process for preparing 5,6-dihydro-5-azacytidine as an antitumor agent  
IN Piskala, Alois; Cesnekova, Barbara; Vesely, Jiri  
PA Czech.  
SO Czech., 6 pp.  
CODEN: CZXXA9  
DT Patent  
LA Czech  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 264456	B1	19890814	CS 1987-6306	19870828
PRAI	CS 1987-6306		19870828		
OS	CASREACT 113:212582; MARPAT 113:212582				
IT	130518-69-3P 130518-70-6P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and deprotection of)				
RN	130518-69-3 CAPLUS				
CN	1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-, acetate (9CI) (CA INDEX NAME)				

CM 1


CRN 114522-15-5  
CMF C29 H26 N4 O8

Absolute stereochemistry.




CM 2

CRN 64-19-7  
CMF C2 H4 O2



RN 130518-70-6 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl


IT 62402-31-7P, 5,6-Dihydro-5-azacytidine hydrochloride

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 62402-31-7 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-beta-D-ribofuranosyl-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 62488-57-7P, 5,6-Dihydro-5-azacytidine

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, by reduction of azacytidine)

RN 62488-57-7 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-beta-D-ribofuranosyl-,  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/816,161 ALW

10/816,161 ALW


L4 ANSWER 63 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1990:158806 CAPLUS  
DN 112:158806  
TI Synthesis, molecular conformation and biological activity of  
6-amino-5-azacytidine  
AU Piskala, Alois; Hanna, Naeem B.; Zajicek, Jaroslav; Cihak, Alois  
CS Inst. Org. Chem. Biochem., Czech. Acad. Sci., Prague, 166 10, Czech.  
SO Collection of Czechoslovak Chemical Communications (1989), 54(9), 2502-12  
CODEN: CCCCAK; ISSN: 0010-0765  
DT Journal  
LA English  
OS CASREACT 112:158806  
IT 105331-00-8P, 6-Amino-5-azacytidine  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and bioactivity of)  
RN 105331-00-8 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4,6-diamino-1- $\beta$ -D-ribofuranosyl- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



IT 65370-91-4P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and bioactivity of, inactive bactericide)  
RN 65370-91-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 6-amino-3- $\beta$ -D-ribofuranosyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



IT 126193-22-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and debenzoylation of)  
RN 126193-22-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 6-amino-3-(2,3,5-tri-O-benzoyl- $\beta$ -D-  
ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/816,161 ALW






10/816,161 ALW


L4 ANSWER 64 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1990:99111 CAPLUS  
DN 112:99111  
TI Synthesis of oligonucleotides containing 5,6-dihydro-5-azacytosine and  
5-azacytosine at specific CpG sites  
AU Goddard, Amanda J.; Marquez, Victor E.  
CS Lab. Med. Chem., Natl. Cancer Inst., Bethesda, MD, 20892, USA  
SO Nucleosides & Nucleotides (1989), Volume Date 1988, 8(5-6), 1015-18  
CODEN: NUNUD5; ISSN: 0732-8311  
DT Journal  
LA English  
IT 117399-78-7  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(conversion of the dihydroazacytosine moiety to azacytosine in)  
RN 117399-78-7 CAPLUS  
CN Thymidine, 2'-deoxy-5,6-dihydro-5-azacytidyl-(3'→5')- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



IT 114522-16-6  
RL: PROC (Process)  
(conversion of, to azacytosine)  
RN 114522-16-6 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-  
pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 65 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1990:72000 CAPLUS  
DN 112:72000  
TI TFT and 6TG resistance of mouse lymphoma cells to analogs of azacytidine  
AU McGregor, Douglas B.; Brown, Alison G.; Cattanach, Pam; Shepherd, Wendy;  
Riach, Colin; Daston, Diane S.; Caspary, William J.  
CS Inveresk Res. Int. Ltd., Musselburgh, EH21 7UB, UK  
SO Carcinogenesis (1989), 10(11), 2003-8  
CODEN: CRNGDP; ISSN: 0143-3334  
DT Journal  
LA English  
IT 62488-57-7, 5,6-Dihydro-5-azacytidine  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(mutagenicity of, in lymphoma cells, tk locus in relation to)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 66 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1989:626122 CAPLUS  
DN 111:226122  
TI Activation and demethylation of the intracisternal A particle genes by  
5-azacytidine  
AU Davis, Caroline M.; Constantinides, Phillip G.; Van der Riet, Fritz; Van  
Schalkwyk, Lynette; Gevers, Wieland; Parker, M. Iqbal  
CS Med. Sch., Univ. Cape Town, Observatory, 7925, S. Afr.  
SO Cell Differentiation and Development (1989), 27(2), 83-93  
CODEN: CDDEE8; ISSN: 0922-3371  
DT Journal  
LA English  
IT 62488-57-7, 5,6-Dihydro-5-azacytidine  
RL: PRP (Properties)  
(intracisternal A particle genes activation and demethylation by, in  
mouse embryo fibroblasts)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.







10/816,161 ALW


L4 ANSWER 67 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1989:554311 CAPLUS  
DN 111:154311  
TI Automated solid phase synthesis of DNA containing 5-azacytosine  
IN Marques, V.; Goddard, A. J.  
PA United States Dept. of Health and Human Services, USA  
SO U. S. Pat. Appl., 22 pp. Avail. NTIS Order No. PAT-APPL-6-178 153.  
CODEN: XAXXAV  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 178153	A0	19880915	US 1988-178153	19880406
	US 5324831	A	19940628		
	CA 1330960	C	19940726	CA 1989-595701	19890405
	WO 8909779	A1	19891019	WO 1989-US1395	19890406
	W: AU, JP				
	AU 8933681	A	19891103	AU 1989-33681	19890406
	AU 625295	B2	19920709		
	JP 03502577	T	19910613	JP 1989-504376	19890406
	JP 06092435	B	19941116		
PRAI	US 1988-178153	A	19880406		
	WO 1989-US1395	A	19890406		
IT	117399-29-8P 117399-79-8P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, by automated solid-phase synthesis, protected dihydroazacytidine phosphoramidite in)				
RN	117399-29-8 CAPLUS				
CN	Guanosine, thymidyl-(3'→5')-2'-deoxyadenyl-(3'→5')-2'- deoxycytidyl-(3'→5')-2'-deoxyguany-(3'→5')-thymidyl-( (3'→5')-2'-deoxy-5,6-dihydro-5-azacytidyl-(3'→5')-2'- deoxyguany-(3'→5')-2'-deoxycytidyl-(3'→5')-2'- deoxyadenyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.







PAGE 4-A




RN 117399-79-8 CAPLUS

CN Guanosine, thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxy-5,6-dihydro-5-azacytidylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-  
 2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A








PAGE 3-A




PAGE 3-B




L4 ANSWER 68 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1989:489722 CAPLUS  
 DN 111:89722  
 TI Cellular metabolism of 5,6-dihydro-5-azacytidine and its incorporation into DNA and RNA of human lymphoid cells CEM/O and CEM/dCk(-)  
 AU Avramis, Vassilios I.; Powell, William C.; Mecum, Robert A.  
 CS Sch. Med., Univ. South. California, Los Angeles, CA, 90027, USA  
 SO Cancer Chemotherapy and Pharmacology (1989), 24(3), 155-60  
 CODEN: CCPHDZ; ISSN: 0344-5704  
 DT Journal  
 LA English  
 IT 115723-52-9, DHACTP 122277-00-3, DHAdCTP  
 RL: FORM (Formation, nonpreparative)  
 (formation of, as dihydroazacytidine metabolite in leukemia cells of humans, nucleic acid formation and methylation in relation to)  
 RN 115723-52-9 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 122277-00-3 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-3,6-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 62488-57-7, DHAC  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (metabolism of, by leukemia cells of humans, nucleic acid formation and methylation in relation to)  
 RN 62488-57-7 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/816,161 ALW



10/816,161 ALW

L4 ANSWER 69 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1989:69050 CAPLUS  
DN 110:69050  
TI Azapyrimidine analogs: inhibition of viral DNA synthesis and protein  
synthesis in SV40 infected BSC-1 cells  
AU Johnson-Thompson, Marian; Albury, Denise  
CS Dep. Biol., Univ. District of Columbia, Washington, DC, 20005, USA  
SO In Vitro Cellular & Developmental Biology (1988), 24(11), 1114-20  
CODEN: ICDBEO; ISSN: 0883-8364  
DT Journal  
LA English  
IT 62488-57-7, 5,6-Dihydro-5-azacytidine  
RL: BIOL (Biological study)  
(viral DNA formation and protein formation in SV40-infected host cells  
response to)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.





L4 ANSWER 70 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1989:57997 CAPLUS  
DN 110:57997  
TI Synthesis of a phosphoramidite of 2'-deoxy-5,6-dihydro-5-azacytidine. Its potential application in the synthesis of DNA containing dihydro-5-aza and 5-azacytosine bases  
AU Goddard, Amanda J.; Marquez, Victor E.  
CS Lab. Med. Chem., Natl. Cancer Inst., Bethesda, MD, 20892, USA  
SO Tetrahedron Letters (1988), 29(15), 1767-70  
CODEN: TELEAY; ISSN: 0040-4039  
DT Journal  
LA English  
OS CASREACT 110:57997  
IT 117399-29-8P 117399-79-8P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 117399-29-8 CAPLUS  
CN Guanosine, thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxy-5,6-dihydro-5-azacytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A





PAGE 2-A



PAGE 2-B










RN 117399-79-8 CAPLUS

CN Guanosine, thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
deoxy-5,6-dihydro-5-azacytidylyl-(3'→5')-2'-deoxyguanylyl-  
(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-  
2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







IT 117399-78-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)


10/816,161 ALW

(preparation of, intermediate and synthesis of oligonucleotides)

RN 117399-78-7 CAPLUS

CN Thymidine, 2'-deoxy-5,6-dihydro-5-azacytidyl-(3'→5')- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW


L4 ANSWER 71 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1988:485813 CAPLUS  
DN 109:85813  
TI Biochemical pharmacology of 5,6-dihydro-5-azacytidine (DHAC) and DNA hypomethylation in tumor (L1210)-bearing mice  
AU Powell, William C.; Avramis, Vassilios I.  
CS Sch. Med., Univ. Southern California, Los Angeles, CA, 90027, USA  
SO Cancer Chemotherapy and Pharmacology (1988), 21(2), 117-21  
CODEN: CCPHDZ; ISSN: 0344-5704  
DT Journal  
LA English  
IT 115723-52-9  
RL: BIOL (Biological study)  
(as dihydroazacytidine metabolite, leukemia inhibition in relation to)  
RN 115723-52-9 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]- $\beta$ -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 62488-57-7, 5,6-Dihydro-5-azacytidine  
RL: BIOL (Biological study)  
(as leukemia inhibitor, biochem. pharmacol. of)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 72 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1988:466419 CAPLUS  
DN 109:66419  
TI Carcinogenicity and hemoglobin synthesis induction by cytidine analogs  
AU Carr, B. I.; Rahbar, S.; Asmeron, Y.; Riggs, A.; Winberg, C. D.  
CS Dep. Med. Oncol. Ther. Res., City of Hope Natl. Med. Cent., Duarte, CA,  
91010, USA  
SO British Journal of Cancer (1988), 57(4), 395-402  
CODEN: BJCAAI; ISSN: 0007-0920  
DT Journal  
LA English  
IT 62488-57-7, 5,6-Dihydro-5-azacytidine  
RL: BIOL (Biological study)  
(carcinogenicity of and Hb formation induction by)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 73 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1988:450037 CAPLUS  
DN 109:50037  
TI Effects of cytidine analogs on methylation of DNA and retrovirus induction  
AU Rascati, Ralph J.  
CS Dep. Biol., Kennesaw Coll., Marietta, GA, 30061, USA  
SO Mutation Research (1988), 208(1), 21-5  
CODEN: MUREAV; ISSN: 0027-5107  
DT Journal  
LA English  
IT 62488-57-7  
RL: BIOL (Biological study)  
(DNA methylation inhibition by, virus induction in relation to)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW


L4 ANSWER 74 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1988:423285 CAPLUS  
DN 109:23285  
TI Preparation and biological activity of 5,6-dihydro-5-azapyrimidine nucleosides  
AU Piskala, Alois; Cesnekova, Barbara; Vesely, Jiri  
CS Inst. Org. Chem. Biochem., Czech. Acad. Sci., Prague, 166 10, Czech.  
SO Nucleic Acids Symposium Series (1987), 18(Symp. Chem. Nucleic Acid Compon., 7th, 1987), 57-60  
CODEN: NACSD8; ISSN: 0261-3166  
DT Journal  
LA English  
OS CASREACT 109:23285  
IT 62488-57-7P 114522-15-5P 114522-16-6P  
114522-17-7P 114522-18-8P 114522-19-9P  
114522-20-2P 114522-21-3P 114522-22-4P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 114522-15-5 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-(2,3,5-tri-O-benzoyl- $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 114522-16-6 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 114522-17-7 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-α-D-erythro-pentofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 114522-18-8 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 114522-19-9 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-α-D-erythro-pentofuranosyl]-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/816,161 ALW



RN 114522-20-2 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-α-D-arabinofuranosyl-3,6-dihydro-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 114522-21-3 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-(2,3,5-tri-O-benzoyl-β-  
D-arabinofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 114522-22-4 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1-β-D-ribofuranosyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




10/816,161 ALW



10/816,161 ALW


L4 ANSWER 75 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1988:56514 CAPLUS  
DN 108:56514  
TI Silylation-mediated oxidation of 2,2'-anhydro-5,6-dihydro-5-azacytidine  
AU Abbasi, M. M.; El-Wassimi, M. T.; Osman, F. H.; Kamel, M. M.  
CS Fac. Sci., Tanta Univ., Tanta, Egypt  
SO Journal fuer Praktische Chemie (Leipzig) (1987), 329(2), 209-16  
CODEN: JPCEAO; ISSN: 0021-8383  
DT Journal  
LA English  
OS CASREACT 108:56514  
IT 71084-43-0P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and silylation-mediated oxidation of)  
RN 71084-43-0 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1- $\beta$ -D-arabinofuranosyl-3,6-dihydro-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 62402-31-7, 5,6-Dihydro-5-azacytidine hydrochloride  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with 2-acetoxyisobutyryl chloride or cyclization of)  
RN 62402-31-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

10/816,161 ALW

L4 ANSWER 76 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1987:508862 CAPLUS  
DN 107:108862  
TI Inhibition of HTLV-III replication in cell cultures  
AU Sarin, P. S.; Sun, D.; Thornton, A.; Taguchi, Y.  
CS Lab. Tumor Cell Biol., Natl. Cancer Inst., Bethesda, MD, 20892, USA  
SO NATO ASI Series, Series A: Life Sciences (1986), 120 (New Exp. Modalities  
Control Neoplasia), 329-42  
CODEN: NALSDJ; ISSN: 0258-1213  
DT Journal; General Review  
LA English  
IT 62488-57-7, NSC 264-880  
RL: BIOL (Biological study)  
(human T-cell leukemia virus-III infection inhibition by)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 77 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1987:489460 CAPLUS  
DN 107:89460  
TI Effect of 5-azacytidine and congeners on DNA methylation and expression of  
deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and  
CCRF/CEM/dCk-  
AU Antonsson, Bruno E.; Avramis, Vassilios I.; Nyce, Jonathan; Holcenberg,  
John S.  
CS Sch. Med., Univ. Southern California, Los Angeles, CA, 90027, USA  
SO Cancer Research (1987), 47(14), 3672-8  
CODEN: CNREA8; ISSN: 0008-5472  
DT Journal  
LA English  
IT 62488-57-7, 5,6-Dihydro-5-azacytidine  
RL: BIOL (Biological study)  
(DNA methylation and deoxycytidine kinase expression response to, in  
neoplasm cells of humans)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW


L4 ANSWER 78 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1987:102638 CAPLUS  
DN 106:102638  
TI 4-Amino-2,6-dihydroxy-1-(2-deoxy-D-ribofuranosyl)-s-triazines  
AU Pochet, Sylvie; Tam Huynh Dinh  
CS Dep. Biochim. Genet. Mol., Inst. Pasteur, Paris, 75724/15, Fr.  
SO Nucleosides & Nucleotides (1986), 5(2), 153-7  
CODEN: NUNUD5; ISSN: 0732-8311  
DT Journal  
LA French  
OS CASREACT 106:102638  
IT 106966-52-3P 106966-53-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and deacylation of)  
RN 106966-52-3 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 6-amino-3-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\alpha$ -D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 106966-53-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 6-amino-3-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\beta$ -D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 106966-54-5P 106966-55-6P  
RL: SPN (Synthetic preparation); PREP (Preparation)


10/816,161 ALW

(preparation of)

RN 106966-54-5 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 6-amino-3-(2-deoxy- $\alpha$ -D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 106966-55-6 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 6-amino-3-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 79 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1987:12497 CAPLUS  
DN 106:12497  
TI In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitor cells  
AU Ajani, J. A.; Spitzer, G.; Tomasovic, B.; Drewinko, B.; Hug, V. M.; Dicke, K.  
CS M. D. Anderson Hosp. Tumor Inst., Univ. Texas, Houston, TX, 77030, USA  
SO British Journal of Cancer (1986), 54(4), 607-13  
CODEN: BJCAAI; ISSN: 0007-0920  
DT Journal  
LA English  
IT 62488-57-7  
RL: PRP (Properties)  
(cytotoxicity of, to bone marrow granulocyte-macrophage progenitor cells of human)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/816,161 ALW

L4 ANSWER 80 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1987:5377 CAPLUS  
DN 106:5377  
TI 6-Amino-5-azacytosine nucleosides  
IN Piskala, Alois; Cihak, Alois; Vesely, Jiri  
PA Czech.  
SO Czech., 6 pp.  
CODEN: CZXXA9  
DT Patent  
LA Czech  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 229068	B1	19840514	CS 1981-6412	19810828
PRAI	CS 1981-6412		19810828		
IT	105331-04-2P				


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and deprotection of)  
RN 105331-04-2 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4,6-diamino-1-[2-deoxy-3,5-bis-O-(4-  
methylbenzoyl)- $\beta$ -D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 105331-00-8P, 6-Amino-5-azacytidine 105331-01-9P,  
6-Amino-2'-deoxy-5-azacytidine  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as bactericide and adenine kinase inhibitor)  
RN 105331-00-8 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4,6-diamino-1- $\beta$ -D-ribofuranosyl- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.






10/816,161 ALW

RN 105331-01-9 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4,6-diamino-1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 81 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1987:330 CAPLUS  
DN 106:330  
TI Differences in DNA damage produced by incorporation of  
5-aza-2'-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian  
cells  
AU Covey, Joseph M.; D'Incalci, Maurizio; Tilchen, Eugene J.; Zaharko, Daniel  
S.; Kohn, Kurt W.  
CS Lab. Mol. Pharmacol., Natl. Cancer Inst., Bethesda, MD, 20892, USA  
SO Cancer Research (1986), 46(11), 5511-17  
CODEN: CNREA8; ISSN: 0008-5472  
DT Journal  
LA English  
IT 62488-57-7, 5,6-Dihydro-5-azacytidine  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(DNA damage from, in human tumor cells)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 82 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1986:28510 CAPLUS  
DN 104:28510  
TI Inhibition of uridine kinase and the salvage of uridine by modified  
pyrimidine nucleosides  
AU Moyer, James D.; Karle, Jean M.; Malinowski, Nancy; Marquez, Victor E.;  
Salam, Mohammed A.; Malspeis, Louis; Cysyk, Richard L.  
CS Lab. Biol. Chem., Natl. Cancer Inst., Bethesda, MD, 20205, USA  
SO Molecular Pharmacology (1985), 28(5), 454-60  
CODEN: MOPMA3; ISSN: 0026-895X  
DT Journal  
LA English  
IT 62488-57-7  
RL: BIOL (Biological study)  
(uridine kinase and uridine salvage inhibition by, neoplasm inhibition  
in relation to)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 83 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1985:400267 CAPLUS  
DN 103:267  
TI Plasma kinetics and effects of 5,6-dihydro-5-azacytidine in mice and L1210 tumor  
AU Zaharko, Daniel S.; Covey, Joseph M.; Kelley, James A.  
CS Lab. Med. Chem. Pharmacol., Natl. Cancer Inst., Bethesda, MD, 20205, USA  
SO Investigational New Drugs (1985), 3(1), 35-41  
CODEN: INNDDK; ISSN: 0167-6997  
DT Journal  
LA English  
IT 62488-57-7  
RL: PRP (Properties)  
(cytotoxicity and plasma kinetics of)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 84 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1985:89680 CAPLUS  
DN 102:89680  
TI Analogs of nucleosides. XL. Inhibition of nucleic acid synthesis in  
L1210 cells by nucleoside analogs  
AU Beranek, Jiri; Acton, Edward M.  
CS Inst. Org. Chem. Biochem., Czech. Acad. Sci., Prague, 166 10/6, Czech.  
SO Collection of Czechoslovak Chemical Communications (1984), 49(11), 2551-6  
CODEN: CCCCAK; ISSN: 0366-547X  
DT Journal  
LA English  
IT 94696-65-8  
RL: BIOL (Biological study)  
(DNA and RNA formation response to, structure in relation to)  
RN 94696-65-8 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1-[5-O-(methylsulfonyl)- $\beta$ -D-  
ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 85 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1984:624991 CAPLUS  
DN 101:224991  
TI Determination of the complete correlation between the sugar ring puckers  
and 5'-exocyclic group rotamers in conformationally-flexible nucleic acid  
components from NMR study  
AU Remin, Mieczyslaw  
CS Inst. Exp. Phys., Univ. Warsaw, Warsaw, 02-089, Pol.  
SO Journal of Biomolecular Structure & Dynamics (1984), 2(1), 211-20  
CODEN: JBSDD6; ISSN: 0739-1102  
DT Journal  
LA English  
IT 22432-96-8  
RL: PRP (Properties)  
(conformational forms of, isomerization in relation to)  
RN 22432-96-8 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1- $\beta$ -D-ribofuranosyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



10/816,161 ALW


L4 ANSWER 86 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1984:525954 CAPLUS  
DN 101:125954  
TI Mechanisms and products of photosensitized degradation of nucleic acids  
and related model compounds  
AU Cadet, J.; Decarroz, C.; Wang, S. Y.; Midden, W. R.  
CS Dep. Rech. Fondam., Cent. Etud. Nucl. Grenoble, Grenoble, F.38041, Fr.  
SO Israel Journal of Chemistry (1983), 23(4), 420-9  
CODEN: ISJCAT; ISSN: 0021-2148  
DT Journal  
LA English  
IT 91990-91-9  
RL: FORM (Formation, nonpreparative)  
(formation of, from diacetyldeoxyguanosine photosensitized oxidation)  
RN 91990-91-9 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(3,5-di-O-acetyl-2-deoxy- $\beta$ -D-  
erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 87 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1984:465432 CAPLUS  
 DN 101:65432  
 TI Reverse phase HPLC determination of 5,6-dihydro-5-azacytidine in biological fluids  
 AU Huguenin, Philipp N.; Jayaram, Hiremagalur N.; Kelley, James A.  
 CS Lab. Med. Chem. Biol., Natl. Cancer Inst., Bethesda, MD, 20205, USA  
 SO Journal of Liquid Chromatography (1984), 7(7), 1433-53  
 CODEN: JLCHD8; ISSN: 0148-3919  
 DT Journal  
 LA English  
 IT 62488-57-7  
 RL: ANT (Analyte); ANST (Analytical study)  
 (determination and pharmacokinetics of, in blood and urine of humans and laboratory animals, HPLC in)  
 RN 62488-57-7 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 91254-61-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as internal standard for dihydroazacytidine determination in blood and urine of humans and laboratory animals by HPLC)  
 RN 91254-61-4 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(5-chloro-5-deoxy- $\beta$ -D-ribofuranosyl)-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 62402-31-7  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, with thionyl chloride)  
 RN 62402-31-7 CAPLUS  
 CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-, monohydrochloride (9CI) (CA INDEX NAME)



10/816,161 ALW

Absolute stereochemistry.




● HCl

10/816,161 ALW

L4 ANSWER 88 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1984:121554 CAPLUS  
DN 100:121554  
TI Nucleosides  
IN Skulnick, Harvey I.  
PA Upjohn Co. , USA  
SO U.S., 19 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4423212	A	19831227	US 1980-217935	19801218
PRAI	US 1980-217935		19801218		
OS	CASREACT 100:121554; MARPAT 100:121554				
IT	66840-52-6P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation and acylation of, with lauroyl chloride)				
RN	66840-52-6 CAPLUS				
CN	1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-5-O-[(1,1-dimethylethyl)dimethylsilyl]-β-D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



IT 66515-69-3P 66678-80-6P 66678-84-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and deacylation of)  
RN 66515-69-3 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/816,161 ALW



RN 66678-80-6 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]-5-ethylidihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 66678-84-0 CAPLUS


CN 1,3,5-Triazine-2,4(1H,3H)-dione, 5-butyl-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 66678-86-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and desilylation of)  
 RN 66678-86-2 CAPLUS  
 CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-5-O-[(1,1-dimethylethyl)dimethylsilyl]-3-O-(1-oxododecyl)-β-D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 57350-36-4P 66678-81-7P 66678-85-1P  
 66678-87-3P 66687-59-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 57350-36-4 CAPLUS  
 CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy-β-D-erythro-pentofuranosyl)dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/816,161 ALW



RN 66678-81-7 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy-β-D-erythro-pentofuranosyl)-5-ethyldihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 66678-85-1 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 5-butyl-1-(2-deoxy-β-D-erythro-pentofuranosyl)dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 66678-87-3 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3-O-(1-oxododecyl)-β-D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/816,161 ALW



RN 66687-59-0 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\alpha$ -D-erythro-pentofuranosyl]-5-ethyldihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 89 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1984:12646 CAPLUS  
DN 100:12646  
TI Bisulfite stabilization of 5-azacytidine  
IN Chatterji, Dulal C.; Gallelli, Joseph F.  
PA United States Dept. of Health and Human Services, USA  
SO U.S., 6 pp. Cont.-in-part of U.S. Ser. No. 163,521, abandoned.  
CODEN: USXXAM

DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4405611	A	19830920	US 1981-331989	19811218
	US 163521	A0	19810731	US 1980-163521	19800627
PRAI	US 1980-163521	A2	19800627		
IT	88192-81-8P				


RL: PREP (Preparation)

(preparation of, for infusion stabilization)

RN 88192-81-8 CAPLUS

CN 1,3,5-Triazine-2-sulfonic acid, 6-amino-1,2,3,4-tetrahydro-4-oxo-3-β-D-ribofuranosyl-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

10/816,161 ALW

L4 ANSWER 90 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1983:432762 CAPLUS  
DN 99:32762  
TI Inhibition of DNA methylation by 5-azacytidine  
AU Jones, P. A.; Taylor, S. M.; Wilson, V. L.  
CS Sch. Med., Univ. South. California, Los Angeles, CA, 90027, USA  
SO Recent Results in Cancer Research (1983), 84 (Modif. Nucleosides Cancer),  
202-11  
CODEN: RRCRBU; ISSN: 0080-0015  
DT Journal  
LA English  
IT 62488-57-7  
RL: BIOL (Biological study)  
(DNA methylation inhibition by, structure in relation to)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.






10/816,161 ALW

L4 ANSWER 91 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1983:432754 CAPLUS  
DN 99:32754  
TI Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound  
AU Malspeis, Louis; Cheng, Haiyung; Staubus, Alfred E.  
CS Cancer Cent., Ohio State Univ., Columbus, OH, 43210, USA  
SO Investigational New Drugs (1983), 1(1), 47-58  
CODEN: INNDDK; ISSN: 0167-6997  
DT Journal  
LA English  
IT 62402-31-7  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
(Biological study); PROC (Process)  
(pharmacokinetics of)  
RN 62402-31-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

10/816,161 ALW

L4 ANSWER 92 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1983:172693 CAPLUS  
DN 98:172693  
TI Drug control of Ara-C-resistant tumor cells  
AU Schabel, F. M., Jr.; Skipper, H. E.; Trader, M. W.; Brockman, R. W.;  
Laster, W. R., Jr.; Corbett, T. H.; Griswold, D. P., Jr.  
CS Dep. Chemother., South. Res. Inst., Birmingham, AL, 35255, USA  
SO Medical and Pediatric Oncology (1982), (Suppl. 1, 1982), 125-48  
CODEN: MPONDB; ISSN: 0098-1532  
DT Journal  
LA English  
IT 62488-57-7  
RL: BIOL (Biological study)  
(Ara-C-resistant tumor cells response to)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 93 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1983:49430 CAPLUS  
DN 98:49430  
TI Mechanism of action of eukaryotic DNA methyltransferase. Use of  
5-azacytosine-containing DNA  
AU Taylor, Shirley M.; Jones, Peter A.  
CS Div. Hematol.-Oncol., Child. Hosp. Los Angeles, Los Angeles, CA, 90027,  
USA  
SO Journal of Molecular Biology (1982), 162(3), 679-92  
CODEN: JMOBAK; ISSN: 0022-2836  
DT Journal  
LA English  
IT 62488-57-7  
RL: BIOL (Biological study)  
(spleen cultured cells treated with, DNA methyltransferase activity in)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 94 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1983:11095 CAPLUS  
DN 98:11095  
TI Pharmacokinetic studies of 5,6-dihydro-5-azacytidine in the dog and human  
urinary metabolites of m-AMSA  
AU Cheng, Haiyung  
CS Ohio State Univ., Columbus, OH, USA  
SO (1982) 183 pp. Avail.: Univ. Microfilms Int., Order No. DA8222062  
From: Diss. Abstr. Int. B 1982, 43(5), 1500  
DT Dissertation  
LA English  
IT 62488-57-7  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
(Biological study); PROC (Process)  
(pharmacokinetics of)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 95 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1982:556091 CAPLUS  
DN 97:156091  
TI Intravenous lethality study in CDFI mice and toxicity study in beagle dogs  
of dihydro-5-azacytidine hydrochloride (NSC-264880) task I  
AU Chin, Arthur E.; Stromberg, Paul C.; Whalen, John E.  
CS Battelle Columbus Labs., Columbus, OH, USA  
SO Report (1981), BCL-AEC-264880-81-1; Order No. PB82-195751, 207 pp.  
From: Gov. Rep. Announce. Index (U. S.) 1982, 82(16), 3193  
DT Report  
LA English  
IT 62402-31-7  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(toxicity of)  
RN 62402-31-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

10/816,161 ALW

L4 ANSWER 96 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1982:155156 CAPLUS  
DN 96:155156  
TI Mutagenicity of 5-azacytidine and related nucleosides in C3H/10T1/2 clone  
8 and V79 cells  
AU Landolph, Joseph R.; Jones, Peter A.  
CS Sch. Med., Univ. South. California, Los Angeles, CA, 90033, USA  
SO Cancer Research (1982), 42(3), 817-23  
CODEN: CNREA8; ISSN: 0008-5472  
DT Journal  
LA English  
IT 62488-57-7  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(mutagenicity of, in C3H/10T1/2 and V-79 cells)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 97 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1982:45969 CAPLUS  
DN 96:45969  
TI The comparative effects of 5-azacytidine and dihydro-5-azacytidine on  
polysomal RNA in Ehrlich ascites cells in vitro  
AU Lin, Hsin Li; Glazer, Robert I.  
CS Lab. Med. Chem. Biol., Natl. Cancer Inst., Bethesda, MD, 20205, USA  
SO Molecular Pharmacology (1981), 20(3), 644-8  
CODEN: MOPMA3; ISSN: 0026-895X  
DT Journal  
LA English  
IT 62488-57-7  
RL: BIOL (Biological study)  
(polysomal RNA activity response to, in Ehrlich ascites cell, antitumor  
activity in relation to)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 98 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1982:32363 CAPLUS  
DN 96:32363  
TI Induction of differentiation of human promyelocytic leukemia cells (HL-60)  
by nucleosides and methotrexate  
AU Bodner, Anne J.; Ting, Robert C.; Gallo, Robert C.  
CS Biotech Res. Lab., Rockville, MD, 20850, USA  
SO JNCI, Journal of the National Cancer Institute (1981), 67(5), 1025-30  
CODEN: JJIND8; ISSN: 0198-0157  
DT Journal  
LA English  
IT 62488-57-7  
RL: BIOL (Biological study)  
(myeloid cell differentiation induction by)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.






10/816,161 ALW

L4 ANSWER 99 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1982:11656 CAPLUS  
DN 96:11656  
TI Bisulfite stabilization of 5-azacytidine  
IN Chatterji, Dulal C.; Gallelli, Joseph F.  
PA United States Dept. of Health and Human Services, USA  
SO U. S. Pat. Appl., 17 pp. Avail. NTIS Order No. PAT-APPL-163 521.  
CODEN: XAXXAV  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 163521	A0	19810731	US 1980-163521	19800627
	US 4405611	A	19830920	US 1981-331989	19811218
PRAI	US 1980-163521	A2	19800627		
IT	79923-62-9P				
	RL: PREP (Preparation) (preparation of, for azacytidine prodrug)				
RN	79923-62-9 CAPLUS				
CN	1,3,5-Triazine-1(2H)-sulfonic acid, 6-amino-3,4-dihydro-4-oxo-3-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



10/816,161 ALW


L4 ANSWER 100 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1981:533287 CAPLUS  
DN 95:133287  
TI Investigations of the mechanism of nucleosides synthesis. Part II.  
Stereochemical control as a function of protecting-group participation in  
2-deoxy-D-erythro-pentofuranosyl nucleosides  
AU Wierenga, Wendall; Skulnick, Harvey I.  
CS Exp. Chem. Res., Upjohn Co., Kalamazoo, MI, 49001, USA  
SO Carbohydrate Research (1981), 90(1), 41-52  
CODEN: CRBRAT; ISSN: 0008-6215  
DT Journal  
LA English  
IT 78138-00-8P 78138-01-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn and debenzylation of)  
RN 78138-00-8 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(phenylmethyl)-  
 $\beta$ -D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 78138-01-9 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(phenylmethyl)-  
 $\alpha$ -D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 57350-36-4P 66515-69-3P 66515-70-6P  
66515-71-7P 78137-97-0P 78137-98-1P  
78137-99-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 57350-36-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\beta$ -D-erythro-  
pentofuranosyl)dihydro-5-methyl- (9CI) (CA INDEX NAME)

10/816,161 ALW


Absolute stereochemistry.



RN 66515-69-3 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\beta$ -D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 66515-70-6 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\alpha$ -D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/816,161 ALW

RN 66515-71-7 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\alpha$ -D-erythro-pentofuranosyl) dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 78137-97-0 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-5-O-(4-methylbenzoyl)-3-O-(phenylmethyl)- $\alpha$ -D-erythro-pentofuranosyl] dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 78137-98-1 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3-O-(4-methylbenzoyl)-5-O-(phenylmethyl)- $\beta$ -D-erythro-pentofuranosyl] dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 78137-99-2 CAPLUS

10/816,161 ALW

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3-O-(4-methylbenzoyl)-5-O-(phenylmethyl)- $\alpha$ -D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 101 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1981:490993 CAPLUS  
DN 95:90993  
TI Contrasting cytotoxicity kinetics of 5-azacytidine and  
dihydro-5-azacytidine hydrochloride in L1210 leukemia in mice  
AU Presant, Cary A.; Coulter, Dean; Valeriote, Frederick; Vietti, Teresa J.  
CS Dep. Med. Oncol., City. of Hope Natl. Med. Cent., Duarte, CA, 91010, USA  
SO JNCI, Journal of the National Cancer Institute (1981), 66(6), 1151-4  
CODEN: JJIND8; ISSN: 0198-0157  
DT Journal  
LA English  
IT 62402-31-7  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(cytotoxicity of)  
RN 62402-31-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

10/816,161 ALW

L4 ANSWER 102 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1981:425542 CAPLUS

DN 95:25542

TI Antiviral 1-(2-deoxy- $\beta$ -D-pentofuranosyl)-5,6-dihydro-s-triazines and derivatives

IN Renis, Harold E.; Skulnick, Harvey I.

PA Upjohn Co., USA

SO U.S., 19 pp. Cont. of U.S. Ser. No. 802,504, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4239753	A	19801216	US 1978-968876	19781212
	US 4477442	A	19841016	US 1980-206311	19801105
PRAI	US 1976-715663	A2	19760819		
	US 1977-802504	A1	19770601		
	US 1978-968876	A1	19781212		
	US 1979-66251	A1	19790809		

OS CASREACT 95:25542; MARPAT 95:25542

IT 57350-36-4P 66678-81-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antiviral activity of)

RN 57350-36-4 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl) dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 66678-81-7 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-5-ethyldihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW


IT 66515-69-3P 66678-80-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and deacylation of)  
RN 66515-69-3 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-  
 $\beta$ -D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 66678-80-6 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-  
 $\beta$ -D-erythro-pentofuranosyl]-5-ethylidihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 66678-86-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and desilylation of)  
RN 66678-86-2 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-5-O-[(1,1-dimethylethyl)dimethylsilyl]-3-O-(1-oxododecyl)- $\beta$ -D-erythro-  
pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



IT 66840-52-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, with lauroyl chloride)

RN 66840-52-6 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-5-O-[(1,1-dimethylethyl)dimethylsilyl]-β-D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 66678-87-3P 66687-59-0P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 66678-87-3 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3-O-(1-oxododecyl)-β-D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/816,161 ALW

RN 66687-59-0 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-  
 $\alpha$ -D-erythro-pentofuranosyl]-5-ethylidihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 103 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1981:132112 CAPLUS  
DN 94:132112  
TI Effects of dihydro-5-azacytidine on cell survival and cell cycle  
progression of cultured mammalian cells  
AU Traganos, Frank; Staiano-Coico, Lisa; Darzynkiewicz, Zbigniew; Melamed,  
Myron R.  
CS Invest. Cytol. Lab., Mem. Sloan-Kettering Cancer Cent., New York, NY,  
10021, USA  
SO Cancer Research (1981), 41(3), 780-9  
CODEN: CNREA8; ISSN: 0008-5472  
DT Journal  
LA English  
IT 62488-57-7  
RL: BIOL (Biological study)  
(cell cycle response to)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry..



10/816,161 ALW

L4 ANSWER 104 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1981:58953 CAPLUS  
DN 94:58953  
TI Contrasting activity of two 5-aza-analogs of cytidine in the induction of  
muscle differentiation in cultured mouse embryo cells  
AU Constantinides, Philip G.; Scott-Burden, Timothy; Gevers, Wieland  
CS Dep. Med. Biochem., Univ. Cape Town Med. Sch., Observatory, 7925, S. Afr.  
SO Biochemistry International (1980), 1(1), 24-31  
CODEN: BIINDF; ISSN: 0158-5231  
DT Journal  
LA English  
IT 62488-57-7  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); BIOL (Biological study)  
(muscle differentiation response to, azacytidine in relation to)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW


L4 ANSWER 105 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1980:472178 CAPLUS  
DN 93:72178  
TI Silylation-mediated oxidation of dihydropyrimidine bases and nucleosides  
AU Kelley, James A.; Abbasi, Mohamed M.; Beisler, John A.  
CS Lab. Med., Chem. Biol., Bethesda, MD, 20205, USA  
SO Analytical Biochemistry (1980), 103(2), 203-13  
CODEN: ANBCA2; ISSN: 0003-2697  
DT Journal  
LA English  
IT 62488-57-7 71084-43-0  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(trimethylsilylation of, dehydrogenation during)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 71084-43-0 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1- $\beta$ -D-arabinofuranosyl-3,6-dihydro-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW


L4 ANSWER 106 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1980:426693 CAPLUS  
DN 93:26693  
TI Investigations of the mechanism of nucleoside synthesis. I. Carbon-13  
NMR studies of dihydro-s-triazine-tin tetrachloride complexes  
AU Wierenga, W.; Skulnick, H. I.  
CS Exp. Chem. Res., Upjohn Co., Kalamazoo, MI, 49001, USA  
SO Tetrahedron Letters (1979), (38), 3631-4  
CODEN: TELEAY; ISSN: 0040-4039  
DT Journal  
LA English  
IT 73804-34-9DP, aroyl derivative  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 73804-34-9 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy-D-erythro-  
pentofuranosyl) dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 107 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1980:215722 CAPLUS  
 Correction of: 1979:23571  
 DN 92:215722  
 Correction of: 90:23571  
 TI 1- $\beta$ -D-Ribofuranosyl-s-triazine-2,4-(1H,3H)-dione (5-azauridine).  
 Direct synthesis of a 5-azapyrimidine ribonucleoside by the  
 Fischer-Helferich procedure  
 AU Piskala, Alois; Sorm, Frantisek  
 CS Inst. Org. Chem. Biochem., Czech. Acad. Sci., Prague, 166 10/6, Czech.  
 SO Nucleic Acid Chem. (1978), Volume 1, 455-9. Editor(s): Townsend, Leroy  
 B.; Tipson, R. Stuart. Publisher: Wiley, New York, N. Y.  
 CODEN: 39GCA6  
 DT Conference  
 LA English  
 IT 59957-73-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and conversion of, to azauridine)  
 RN 59957-73-2 CAPLUS  
 CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-6-methoxy-1-(2,3,5-tri-O-benzoyl- $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 108 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1980:191164 CAPLUS  
DN 92:191164  
TI The comparative effects of 5-azacytidine and dihydro-5-azacytidine on 4 S  
and 5 S nuclear RNA  
AU Glazer, Robert I.; Hartman, Kathleen D.  
CS Lab. Med. Chem. Biol., Natl. Cancer Inst., Bethesda, MD, 20205, USA  
SO Molecular Pharmacology (1980), 17(2), 250-5  
CODEN: MOPMA3; ISSN: 0026-895X  
DT Journal  
LA English  
IT 62488-57-7  
RL: BIOL (Biological study)  
(nuclear RNA formation response to)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.






10/816,161 ALW

L4 ANSWER 109 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1980:191117 CAPLUS  
DN 92:191117  
TI The effect of 5-azacytidine and dihydro-5-azacytidine on nuclear ribosomal  
RNA and poly(A) RNA synthesis in L1210 cells in vitro  
AU Glazer, Robert I.; Peale, Ann L.; Beisler, John A.; Abbasi, Mohamed M.  
CS Appl. Pharmacol. Sect., Natl. Cancer Inst., Bethesda, MD, 20205, USA  
SO Molecular Pharmacology (1980), 17(1), 111-17  
CODEN: MOPMA3; ISSN: 0026-895X  
DT Journal  
LA English  
IT 62488-57-7  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); BIOL (Biological study)  
(RNA formation by neoplasm response to)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW


L4 ANSWER 110 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1980:42320 CAPLUS  
DN 92:42320  
TI A new synthesis of the antiviral nucleoside, dihydro-5-azathymidine, with  
a novel incorporation of 6-substituted analogs  
AU Skulnick, H. I.; Wierenga, W.  
CS Upjohn Co., Kalamazoo, MI, 49001, USA  
SO Journal of Carbohydrates, Nucleosides, Nucleotides (1979), 6(3), 263-77  
CODEN: JCNNAF; ISSN: 0094-0585  
DT Journal  
LA English  
IT 72328-58-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and deacylation of)  
RN 72328-58-6 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-  
 $\beta$ -D-erythro-pentofuranosyl]dihydro-5,6-dimethyl- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.



IT 57350-36-4P 66515-69-3P 66515-70-6P  
66515-71-7P 72328-56-4P 72328-57-5P  
72328-59-7P 72328-60-0P 72328-61-1P  
72328-64-4P 72328-65-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 57350-36-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy-β-D-erythro-  
pentofuranosyl)dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 66515-69-3 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\beta$ -D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 66515-70-6 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\alpha$ -D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/816,161 ALW

RN 66515-71-7 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\alpha$ -D-erythro-pentofuranosyl) dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 72328-56-4 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione-6-d, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\beta$ -D-erythro-pentofuranosyl] dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 72328-57-5 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione-6-d, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\alpha$ -D-erythro-pentofuranosyl] dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/816,161 ALW



RN 72328-59-7 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy-β-D-erythro-pentofuranosyl)dihydro-5,6-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 72328-60-0 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]dihydro-5-methyl-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/816,161 ALW

RN 72328-61-1 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 3-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\beta$ -D-erythro-pentofuranosyl]dihydro-1-methyl-6-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 72328-64-4 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 3-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-D-erythro-pentofuranosyl]dihydro-1,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 72328-65-5 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 3-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\alpha$ -D-erythro-pentofuranosyl]dihydro-1-methyl-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/816,161 ALW



10/816,161 ALW

L4 ANSWER 111 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1980:42251 CAPLUS  
DN 92:42251  
TI Synthesis of 1-(2-deoxy- $\beta$ -D-ribofuranosyl)-5,6-dihydro-5-methyl-s-  
triazine-2,4(1H,3H)dione  
AU Skulnick, H. I.  
CS Upjohn Co., Kalamazoo, MI, 49001, USA  
SO Chem. Biol. Nucleosides Nucleotides, [Pap. Symp.] (1978), Meeting Date  
1976, 211-27. Editor(s): Harmon, Robert E.; Robins, Roland K.; Townsend,  
Leroy B. Publisher: Academic, New York, N. Y.  
CODEN: 41MUAB  
DT Conference; General Review  
LA English  
IT 57350-36-4P  
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)  
(synthesis of)  
RN 57350-36-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\beta$ -D-erythro-  
pentofuranosyl)dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






10/816,161 ALW

L4 ANSWER 112 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1980:42250 CAPLUS  
DN 92:42250  
TI Synthesis and chemistry of a new antiviral antibiotic nucleoside in the anhydro form: application of a novel 1,3-electrophilic (C-N-C) annulation reagent  
AU Wierenga, Wendell; Woltersom, John A.  
CS Exp. Chem. Res., Upjohn Co., Kalamazoo, MI, 49001, USA  
SO Chem. Biol. Nucleosides Nucleotides, [Pap. Symp.] (1978), Meeting Date 1976, 199-210. Editor(s): Harmon, Robert E.; Robins, Roland K.; Townsend, Leroy B. Publisher: Academic, New York, N. Y.  
CODEN: 41MUAB  
DT Conference; General Review  
LA English  
IT 57350-36-4  
RL: RCT (Reactant); RACT (Reactant or reagent)  
RN 57350-36-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl) dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 113 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1979:551221 CAPLUS  
DN 91:151221  
TI Synthesis and antitumor activity of 5-azacytosine arabinoside  
AU Beisler, John A.; Abbasi, Mohamed M.; Driscoll, John S.  
CS Natl. Cancer Inst., NIH, Bethesda, MD, 20014, USA  
SO Journal of Medicinal Chemistry (1979), 22(10), 1230-4  
CODEN: JMCMAR; ISSN: 0022-2623  
DT Journal  
LA English  
IT 65886-72-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and dehydrogenation of)  
RN 65886-72-8 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1- $\beta$ -D-arabinofuranosyl-3,6-dihydro-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 71084-42-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and hydrogenolysis of)  
RN 71084-42-9 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-[2,3,5-tris-O-(  
phenylmethyl)- $\beta$ -D-arabinofuranosyl]-, monohydrochloride (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.

10/816,161 ALW



● HCl


IT 71084-43-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 71084-43-0 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-arabinofuranosyl-3,6-dihydro-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 114 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1979:545908 CAPLUS  
DN 91:145908  
TI Stabilization of 5-azacytidine by nucleophilic addition of bisulfite ion  
AU Chatterji, Dulal C.; Gallelli, Joseph F.  
CS Pharm. Dep., NIH, Bethesda, MD, 20014, USA  
SO Journal of Pharmaceutical Sciences (1979), 68(7), 822-6  
CODEN: JPMSAE; ISSN: 0022-3549  
DT Journal  
LA English  
IT 71288-72-7  
RL: FORM (Formation, nonpreparative)  
(formation of, by nucleophilic addition of bisulfite to azacytidine)  
RN 71288-72-7 CAPLUS  
CN 1,3,5-Triazine-2-sulfonic acid, 6-amino-1,2,3,4-tetrahydro-4-oxo-3- $\beta$ -  
D-ribofuranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 115 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1979:491912 CAPLUS  
DN 91:91912  
TI Barriers to hindered rotation at the N-glycosidic bond. IV.  
1-( $\beta$ -D-Ribofuranosyl)isocyanuric acids  
AU Wegner, Gertrud; Jochims, Johannes C.  
CS Fachber. Chem., Univ. Konstanz, Konstanz, D-7750, Fed. Rep. Ger.  
SO Chemische Berichte (1979), 112(6), 1941-7  
CODEN: CHBEAM; ISSN: 0009-2940  
DT Journal  
LA German  
IT 71109-71-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation, methylation, and NMR of)  
RN 71109-71-2 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(2,3,5-tri-O-acetyl- $\beta$ -D-  
ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 116 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1979:187294 CAPLUS  
DN 90:187294  
TI 2,2'-Anhydrotriazine nucleosides  
IN Wierenga, Wendell  
PA Upjohn Co., USA  
SO U.S., 12 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 4140850	A	19790220	US 1977-828797	19770829
PRAI	US 1977-828797	A	19770829		
OS	MARPAT 90:187294				
IT	66528-44-7P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	66528-44-7	CAPLUS			
CN	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-β-D-arabinofuranosyl-3-methyl- (9CI) (CA INDEX NAME)				

The chemical structure shows a 1-methyl-1H-imidazole-4-carboxamide moiety connected at the 2-position to a 2,3-dihydrothiazole ring. The thiazole ring has a hydroxyl group at the 4-position and a hydroxymethyl group at the 5-position, both with R stereochemistry. The thiazole ring is fused to a five-membered ring containing two sulfur atoms and an oxygen atom, with R stereochemistry at the 2 and 3 positions.

10/816,161 ALW

L4 ANSWER 117 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1979:182436 CAPLUS  
DN 90:182436  
TI Comparative study of oxidation of nucleic acid components by hydroxyl radicals, singlet oxygen and superoxide anion radicals  
AU Cadet, Jean; Teoule, Robert  
CS Dep. Rech. Fondam., CEN, Grenoble, Fr.  
SO Photochemistry and Photobiology (1978), 28(4-5 (Singlet Oxygen Relat. Species Chem. Biol.)), 661-7  
CODEN: PHCBAP; ISSN: 0031-8655  
DT Journal  
LA English  
IT 70165-41-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, by deoxyguanosine oxidation by singlet oxygen)  
RN 70165-41-2 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 118 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1979:145791 CAPLUS  
DN 90:145791  
TI Activities of 5,6-dihydro-5-azathymidine against herpes simplex virus  
infections in mice  
AU Renis, Harold E.; Eidson, Emerson E.  
CS Exp. Biol. Res., Upjohn Co., Kalamazoo, MI, USA  
SO Antimicrobial Agents and Chemotherapy (1979), 15(2), 213-19  
CODEN: AMACCQ; ISSN: 0066-4804  
DT Journal  
LA English  
IT 57350-36-4  
RL: BIOL (Biological study)  
(herpes virus infection treatment with)  
RN 57350-36-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\beta$ -D-erythro-  
pentofuranosyl) dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





L4 ANSWER 119 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1979:23571 CAPLUS  
 DN 90:23571  
 TI 1- $\beta$ -D-Ribofuranosyl-s-triazine-2,4-(1H,3H)-dione (5-azauridine):  
 Direct synthesis of a 5-azapyrimidine ribonucleoside by the  
 Fischer-Helferich procedure  
 AU Piskala, Alois; Sorm, Frantisek  
 CS Inst. Org. Chem. Biochem., Czech. Acad. Sci., Prague, Czech.  
 SO Nucleic Acid Chem. (1978), Volume 1, 455-9. Editor(s): Townsend, Leroy  
 B.; Tipson, R. Stuart. Publisher: Wiley, New York, N. Y.  
 CODEN: 39GCA6  
 DT Conference  
 LA English  
 IT 59957-73-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and deblocking of)  
 RN 59957-73-2 CAPLUS  
 CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-6-methoxy-1-(2,3,5-tri-O-benzoyl-  
 $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 120 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1978:608928 CAPLUS  
DN 89:208928  
TI 5,6-Dihydro-5-azathymidine: in vitro antiviral properties against human  
herpesviruses  
AU Renis, Harold E.  
CS Exp. Biol., Upjohn Co., Kalamazoo, MI, USA  
SO Antimicrobial Agents and Chemotherapy (1978), 13(4), 613-17  
CODEN: AMACCQ; ISSN: 0066-4804  
DT Journal  
LA English  
IT 57350-36-4  
RL: BIOL (Biological study)  
(Herpes simplex virus inhibition by)  
RN 57350-36-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\beta$ -D-erythro-  
pentofuranosyl) dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 121 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1978:540117 CAPLUS  
DN 89:140117  
TI Studies on the cytostatic action, phosphorylation and deamination of  
5-azacytidine and 5,6-dihydro-5-azacytidine in HeLa cells  
AU Futterman, Benjamin; Derr, Jerry; Beisler, John A.; Abbasi, Mohammed M.;  
Voytek, Peter  
CS Natl. Cancer Inst., Natl. Inst. Health, Bethesda, MD, USA  
SO Biochemical Pharmacology (1978), 27(6), 907-9  
CODEN: BCPCA6; ISSN: 0006-2952  
DT Journal  
LA English  
IT 62488-57-7  
RL: BIOL (Biological study)  
(HeLa cell growth response to and metabolism of)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW


L4 ANSWER 122 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1978:490255 CAPLUS  
DN 89:90255  
TI Synthesis of the new nucleoside antibiotic 1-(2-deoxy- $\beta$ -D-ribofuranosyl)-5,6-dihydro-5-methyl-S-triazine-2,4(1H,3H)-dione  
AU Skulnick, Harvey  
CS Exp. Chem. Res., Upjohn Co., Kalamazoo, MI, USA  
SO Journal of Organic Chemistry (1978), 43(16), 3188-94  
CODEN: JOCEAH; ISSN: 0022-3263  
DT Journal  
LA English  
IT 66515-62-6P 66515-69-3P 66515-70-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and deblocking of)  
RN 66515-62-6 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1-methyl-3-(2,3,5-tri-O-benzoyl- $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 66515-69-3 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\beta$ -D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 66515-70-6 CAPLUS

10/816,161 ALW

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-  
 $\alpha$ -D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 64332-50-9P 66515-64-8P 66515-65-9P  
66515-71-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 64332-50-9 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1-methyl-3- $\beta$ -D-ribofuranosyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 66515-64-8 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1-methyl-5-(2,3,5-tri-O-acetyl-  
 $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/816,161 ALW



RN 66515-65-9 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1-methyl-3-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 66515-71-7 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy-alpha-D-erythro-pentofuranosyl)dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 123 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1978:424728 CAPLUS  
DN 89:24728  
TI 5,6-Dihydro-syn(s)-triazinenucleosides and -nucleotides  
IN Skulnick, Harvey Irving  
PA Upjohn Co., USA  
SO Ger. Offen., 84 pp.  
CODEN: GWXXBX  
DT Patent  
LA German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2735378	A1	19780223	DE 1977-2735378	19770805
	DE 2735378	C2	19890511		
	US 4171431	A	19791016	US 1977-802555	19770601
	NL 7709010	A	19780221	NL 1977-9010	19770816
	JP 53025583	A	19780309	JP 1977-99429	19770819
	JP 61033038	B	19860731		
	FR 2362158	A1	19780317	FR 1977-25483	19770819
	FR 2362158	B1	19800711		
PRAI	US 1976-715664	A	19760819		
	US 1977-802555	A	19770601		


OS MARPAT 89:24728

IT 66840-52-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and acylation of)

RN 66840-52-6 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-5-O-[(1,1-dimethylethyl)dimethylsilyl]- $\beta$ -D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)




IT 66515-69-3P 66678-84-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and deacylation of)

RN 66515-69-3 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\beta$ -D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 66678-84-0 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 5-butyl-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 66678-80-6P 66678-86-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and deblocking of)


RN 66678-80-6 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]-5-ethyldihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/816,161 ALW



RN 66678-86-2 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-5-O-[(1,1-dimethylethyl)dimethylsilyl]-3-O-(1-oxododecyl)-β-D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 66678-81-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and virucidal activity of)

RN 66678-81-7 CAPLUS


CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy-β-D-erythro-pentofuranosyl)-5-ethyldihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 66678-85-1P 66678-87-3P 66687-59-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 66678-85-1 CAPLUS  
 CN 1,3,5-Triazine-2,4(1H,3H)-dione, 5-butyl-1-(2-deoxy-β-D-erythro-pentofuranosyl)dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 66678-87-3 CAPLUS  
 CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3-O-(1-oxododecyl)-β-D-erythro-pentofuranosyl]dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 66687-59-0 CAPLUS  
 CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-α-D-erythro-pentofuranosyl]-5-ethylidihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 57350-36-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, silylation, and virucidal activity of)

RN 57350-36-4 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy-β-D-erythro-pentofuranosyl) dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW


L4 ANSWER 124 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1978:416857 CAPLUS  
DN 89:16857  
TI  $\beta$ -D-Arabinofuran[1',2':4,5]oxazolo-1,3,5-triazine-5-N-methyl-4,6-  
dione and analogs, unusually specific immunosuppressive agents  
AU Wierenga, W.; Loughman, B. E.; Gibbons, A. J.; Renis, H. E.  
CS Exp. Chem. Res., Upjohn Co., Kalamazoo, MI, USA  
SO Journal of Medicinal Chemistry (1978), 21(6), 558-62  
CODEN: JMCMAR; ISSN: 0022-2623  
DT Journal  
LA English  
IT 66528-44-7P 66528-45-8P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
study); PREP (Preparation)  
(preparation and immunosuppressive and antiviral activity of)  
RN 66528-44-7 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1- $\beta$ -D-arabinofuranosyl-3-  
methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 66528-45-8 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-methyl-3-(2,3,5-tri-O-acetyl-  
 $\beta$ -D-arabinofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 125 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1978:182719 CAPLUS  
DN 88:182719  
TI The synthesis and antitumor activity of arabinosyl-5-azacytosine  
AU Beisler, John A.; Abbasi, Mohamed M.; Driscoll, John S.  
CS Natl. Cancer Inst., Natl. Inst. Health, Bethesda, MD, USA  
SO Biochemical Pharmacology (1977), 26(24), 2469-72  
CODEN: BCPA6; ISSN: 0006-2952  
DT Journal  
LA English  
IT 65886-72-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and dehydrogenation of)  
RN 65886-72-8 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1- $\beta$ -D-arabinofuranosyl-3,6-dihydro-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

10/816,161 ALW


L4 ANSWER 126 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1978:121625 CAPLUS  
DN 88:121625  
TI Introduction of a new 1,3-electrophilic carbon-nitrogen-carbon annulation reagent in the synthesis of 2,2'-anhydrodihydro-5-azathymidine  
AU Wierenga, Wendell; Woltersom, John A.  
CS Exp. Chem. Res., Upjohn Co., Kalamazoo, MI, USA  
SO Journal of Organic Chemistry (1978), 43(4), 529-35  
CODEN: JOCEAH; ISSN: 0022-3263  
DT Journal  
LA English  
IT 57350-36-4 64332-48-5 64332-50-9  
RL: PRP (Properties)  
(carbon-13 NMR spectrum of)  
RN 57350-36-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 64332-48-5 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1-methyl-5-(2,3,5-tri-O-acetyl- $\beta$ -D-arabinofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 64332-50-9 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-1-methyl-3- $\beta$ -D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/816,161 ALW




IT 64332-49-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 64332-49-6 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-[3,5-bis-O-[(1,1-dimethylethyl)dimethylsilyl]-β-D-arabinofuranosyl]dihydro-5-methyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW


L4 ANSWER 127 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1978:62568 CAPLUS  
DN 88:62568  
TI Chemistry of antitumor triazine nucleosides. An improved synthesis of dihydro-5-azacytidine  
AU Beisler, John A.; Abbasi, Mohamed M.; Kelley, James A.; Driscoll, John S.  
CS Natl. Cancer Inst., NIH, Bethesda, MD, USA  
SO Journal of Carbohydrates, Nucleosides, Nucleotides (1977), 4(5), 281-99  
CODEN: JCNNAF; ISSN: 0094-0585  
DT Journal  
LA English  
IT 65370-91-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and acid hydrolysis of)  
RN 65370-91-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 6-amino-3- $\beta$ -D-ribofuranosyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



IT 62402-31-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and dehydrogenation of)  
RN 62402-31-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl



10/816,161 ALW

L4 ANSWER 128 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1977:511349 CAPLUS  
DN 87:111349  
TI Comparative studies of the cytostatic action and metabolism of  
5-azacytidine and 5,6-dihydro-5-azacytidine  
AU Voytek, P.; Beisler, J. A.; Abbasi, M. M.; Wolpert-DeFilippes, M. K.  
CS Natl. Cancer Inst., NIH, Bethesda, MD, USA  
SO Cancer Research (1977), 37(7, Pt. 1), 1956-61  
CODEN: CNREA8; ISSN: 0008-5472  
DT Journal  
LA English  
IT 62402-31-7  
RL: PROC (Process)  
(cytostatic activity and metabolism of, in leukemic cells)  
RN 62402-31-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

10/816,161 ALW

L4 ANSWER 129 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1977:478444 CAPLUS  
DN 87:78444  
TI Efficacy of 5,6-dihydro-5-azathymidine against cutaneous herpes simplex virus in hairless mice  
AU Underwood, Gerald E.; Weed, Sheldon D.  
CS Exp. Biol., Upjohn Co., Kalamazoo, MI, USA  
SO Antimicrobial Agents and Chemotherapy (1977), 11(4), 765-7  
CODEN: AMACCQ; ISSN: 0066-4804  
DT Journal  
LA English  
IT 57350-36-4  
RL: BIOL (Biological study)  
(herpes simplex virus prophylaxis and treatment with)  
RN 57350-36-4 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl) dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 130 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1977:462862 CAPLUS

DN 87:62862

TI The synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine

IN Beisler, John A.; Abbasi, Mohamed M.; Driscoll, John S.

PA United States Dept. of Health, Education, and Welfare, USA

SO U. S. Pat. Appl., 17 pp. Avail. NTIS.

CODEN: XAXXAV

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 712854	A0	19760808	US 1976-712854	19760808
PRAI	US 1976-712854		19760808		
IT	62402-31-7P 62488-57-7P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation and antitumor activity of)

RN 62402-31-7 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 62488-57-7 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/816,161 ALW

L4 ANSWER 131 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1977:433521 CAPLUS  
DN 87:33521  
TI Synthesis and antitumor activity of dihydro-5-azacytidine, a  
hydrolytically stable analog of 5-azacytidine  
AU Beisler, John A.; Abbasi, Mohamed M.; Kelley, James A.; Driscoll, John S.  
CS Natl. Cancer Inst., NIH, Bethesda, MD, USA  
SO Journal of Medicinal Chemistry (1977), 20(6), 806-12  
CODEN: JMCMAR; ISSN: 0022-2623  
DT Journal  
LA English  
IT 62402-31-7P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
study); PREP (Preparation)  
(preparation and neoplasm inhibiting activity of)  
RN 62402-31-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-,  
monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 62488-57-7P 63201-34-3P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 62488-57-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-,  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 63201-34-3 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one-6-d, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-,  
monohydrochloride (9CI) (CA INDEX NAME)

10/816,161 ALW

Absolute stereochemistry.



● HCl

10/816,161 ALW

L4 ANSWER 132 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1977:429038 CAPLUS  
DN 87:29038  
TI Therapeutic compositions of antibiotic U-44,590  
IN Bannister, Brian; DeBoer, Clarence; Renis, Harold E.  
PA Upjohn Co., USA  
SO U.S., 19 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4022889	A	19770510	US 1975-586232	19750612
PRAI	US 1974-471309	A1	19740520		
IT	57350-36-4P				


RL: PREP (Preparation)

(preparation of, as bacteriocide and virucide)

RN 57350-36-4 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RL: PREP (Preparation)

(prepn. of, as bactericide and virucide)

10/816,161 ALW

L4 ANSWER 133 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1977:165237 CAPLUS  
DN 86:165237  
TI Dihydro-5-azacytidine hydrochloride, a biologically active and chemically stable analog of 5-azacytidine  
AU Beisler, John A.; Abbasi, Mohamed M.; Driscoll, John S.  
CS Natl. Cancer Inst., NIH, Bethesda, MD, USA  
SO Cancer Treatment Reports (1976), 60(11), 1671-4  
CODEN: CTRRDO; ISSN: 0361-5960  
DT Journal  
LA English  
IT 62402-31-7P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as neoplasm inhibitor)  
RN 62402-31-7 CAPLUS  
CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1- $\beta$ -D-ribofuranosyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

10/816,161 ALW

L4 ANSWER 134 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1976:433348 CAPLUS  
DN 85:33348  
TI Direct synthesis of 5-azapyrimidine ribonucleosides  
AU Piskala, A.; Fiedler, P.; Sorm, Frantisek  
CS Inst. Org. Chem. Biochem., Czech. Acad. Sci., Prague, Czech.  
SO Nucleic Acids Research, Special Publication (1975), 1(Symp. Chem. Nucleic  
Acids Components, 3rd, 1975), S17-S20  
CODEN: NARPD6; ISSN: 0309-1872  
DT Journal  
LA English  
IT 59957-73-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 59957-73-2 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-6-methoxy-1-(2,3,5-tri-O-benzoyl-  
β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






10/816,161 ALW

L4 ANSWER 135 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1976:15683 CAPLUS  
DN 84:15683  
TI Antibiotic U-44,590 by fermentation  
IN DeBoer, Clarence; Bannister, Brian  
PA Upjohn Co., USA  
SO U.S., 13 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3907643	A	19750923	US 1975-541346	19750115
	US 3907779	A	19750923	US 1974-471322	19740520
PRAI	US 1974-471322	A3	19740520		
IT	57350-36-4P 57350-37-5P				
	RL: PREP (Preparation)				
	(preparation of)				
RN	57350-36-4 CAPLUS				
CN	1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl) dihydro-5-methyl- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RN 57350-37-5 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(3,5-di-O-acetyl-2-deoxy- $\beta$ -D-erythro-pentofuranosyl) dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/816,161 ALW

L4 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1976:15682 CAPLUS  
DN 84:15682  
TI 5,6-Dihydro-5-azathymidine and derivatives  
IN DeBoer, Clarence; Bannister, Brian  
PA Upjohn Co., USA  
SO U.S., 13 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3907779	A	19750923	US 1974-471322	19740520
	US 3907643	A	19750923	US 1975-541346	19750115
	ZA 7502598	A	19760331	ZA 1975-2598	19750422
	CA 1037889	A1	19780905	CA 1975-225567	19750424
	GB 1472667	A	19770504	GB 1975-17206	19750425
	AU 7580579	A	19761104	AU 1975-80579	19750428
	JP 50148590	A	19751128	JP 1975-52100	19750501
	JP 58051759	B	19831118		
	DE 2521197	A1	19751211	DE 1975-2521197	19750513
	DE 2521197	C2	19840913		
	NL 7505708	A	19751124	NL 1975-5708	19750515
	FR 2271838	A1	19751219	FR 1975-15539	19750516
	FR 2271838	B1	19781006		
	BE 829268	A1	19751120	BE 1975-156516	19750520
	CA 1056822	A2	19790619	CA 1978-303945	19780524
	JP 59048072	A	19840319	JP 1983-127066	19830714
PRAI	US 1974-471322	A3	19740520		
	CA 1975-225567	A3	19750424		
IT	57350-36-4P 57350-37-5P				
	RL: PREP (Preparation)				
	(preparation of)				
RN	57350-36-4 CAPLUS				
CN	1,3,5-Triazine-2,4(1H,3H)-dione, 1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl) dihydro-5-methyl- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 57350-37-5 CAPLUS  
CN 1,3,5-Triazine-2,4(1H,3H)-dione, 1-(3,5-di-O-acetyl-2-deoxy- $\beta$ -D-erythro-pentofuranosyl) dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/816,161 ALW



10/816,161 ALW

L4 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1973:453724 CAPLUS  
DN 79:53724  
TI Carbon-13 NMR spectra of C-nucleosides. Showdomycin and  
 $\beta$ -pseudouridine  
AU Chenon, Marie T.; Pugmire, Ronald J.; Grant, David M.; Panzica, Raymond  
P.; Townsend, Leroy B.  
CS Dep. Chem., Univ. Utah, Salt Lake City, UT, USA  
SO Journal of Heterocyclic Chemistry (1973), 10(3), 427-9  
CODEN: JHTCAD; ISSN: 0022-152X  
DT Journal  
LA English  
IT 22432-96-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(carbon-13 NMR spectra in comparison with showdomycin and  
pseudouridine)  
RN 22432-96-8 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1- $\beta$ -D-ribofuranosyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



10/816,161 ALW

L4 ANSWER 138 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1972:502105 CAPLUS  
DN 77:102105  
TI Conformation of the exocyclic 5'-CH<sub>2</sub>OH in nucleosides and nucleotides in aqueous solution from specific assignments of the H5' and H5'' signals in the NMR spectra  
AU Remin, M.; Shugar, D.  
CS Inst. Exp. Phys., Univ. Warsaw, Warsaw, Pol.  
SO Biochemical and Biophysical Research Communications (1972), 48(3), 636-42  
CODEN: BBRCA9; ISSN: 0006-291X  
DT Journal  
LA English  
IT 22432-96-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(conformation of hydroxymethyl group in, NMR spectrum in relation to)  
RN 22432-96-8 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-β-D-ribofuranosyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



10/816,161 ALW

L4 ANSWER 139 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1972:502104 CAPLUS  
DN 77:102104  
TI Proton magnetic resonance study of the influence of base ionization on the  
conformation of pseudouridine  
AU Deslauriers, Roxanne; Smith, Ian C. P.  
CS Biochem. Lab., Natl. Res. Counc. Canada, Ottawa, ON, Can.  
SO Canadian Journal of Biochemistry (1972), 50(7), 766-74  
CODEN: CJBIAE; ISSN: 0008-4018  
DT Journal  
LA English  
IT 22432-96-8  
RL: PRP (Properties)  
(conformation of, base ionization in relation to)  
RN 22432-96-8 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1- $\beta$ -D-ribofuranosyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



10/816,161 ALW

L4 ANSWER 140 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1971:518515 CAPLUS  
DN 75:118515  
TI Correlation of some structural parameters of pyrimidine nucleosides.  
Nuclear magnetic resonance study  
AU Hruska, F. E.; Smith, A. A.; Dalton, J. G.  
CS Chem. Dep., Univ. Manitoba, Fort Garry, MB, Can.  
SO Journal of the American Chemical Society (1971), 93(17), 4334-6  
CODEN: JACSAT; ISSN: 0002-7863  
DT Journal  
LA English  
IT 22432-96-8  
RL: PRP (Properties)  
(conformation of, N.M.R. in relation to)  
RN 22432-96-8 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1- $\beta$ -D-ribofuranosyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



10/816,161 ALW

L4 ANSWER 141 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1971:464185 CAPLUS  
DN 75:64185  
TI Nuclear magnetic resonance study of the conformation of  $\beta$ -cyanuric  
acid riboside. Further evidence for the anti rotamer in pyrimidine  
nucleosides  
AU Smith, Ian C. P.; Dugas, H.; Blackburn, B. J.; Robins, R. K.; Deslauriers,  
Roxanne  
CS Biochem. Lab., Natl. Res. Counc. Canada, Ottawa, ON, Can.  
SO Journal of the American Chemical Society (1971), 93(14), 3468-70  
CODEN: JACSAT; ISSN: 0002-7863  
DT Journal  
LA English  
IT 22432-96-8  
RL: PRP (Properties)  
(nuclear magnetic resonance of, conformation in relation to)  
RN 22432-96-8 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1- $\beta$ -D-ribofuranosyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






10/816,161 ALW

L4 ANSWER 142 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1970:450542 CAPLUS  
DN 73:50542  
TI Carbon-13 magnetic resonance. XVIII. Selected nucleosides  
AU Jones, Alan John; Grant, David M.; Winkley, Michael W.; Robins, Roland K.  
CS Dep. of Chem., Colorado State Univ., Fort Collins, CO, USA  
SO Journal of Physical Chemistry (1970), 74(13), 2684-9  
CODEN: JPCHAX; ISSN: 0022-3654  
DT Journal  
LA English  
IT 22432-96-8  
RL: PRP (Properties)  
(nuclear magnetic resonance of)  
RN 22432-96-8 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1- $\beta$ -D-ribofuranosyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



10/816,161 ALW


L4 ANSWER 143 OF 143 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1970:90799 CAPLUS  
DN 72:90799  
TI Direct glycosylation of 1,3,5-triazinones. New approach to the synthesis of the nucleoside antibiotic 5-azacytidine (4-amino-1- $\beta$ -D-ribofuranosyl-1,3,5-triazin-2-one) and related derivatives  
AU Winkley, Michael W.; Robins, Roland K.  
CS Dep. of Chem., Univ. of Utah, Salt Lake City, UT, USA  
SO Journal of Organic Chemistry (1970), 35(2), 491-5  
CODEN: JOCEAH; ISSN: 0022-3263  
DT Journal  
LA English  
IT 22432-96-8P 22432-97-9P 22432-99-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 22432-96-8 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1- $\beta$ -D-ribofuranosyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 22432-97-9 CAPLUS  
CN s-Triazine-2,4,6(1H,3H,5H)-trione, 1-methyl-3- $\beta$ -D-ribofuranosyl-  
(8CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 22432-99-1 CAPLUS  
CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1-(2,3,5-tri-O-benzoyl- $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/816,161 ALW





chain nodes :

8 14

ring nodes :

1 2 3 4 5 6 9 10 11 12 13

chain bonds :

1-9 2-8 11-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-13 10-11 11-12 12-13

exact/norm bonds :

1-2 1-6 1-9 2-3 2-8 3-4 4-5 5-6

exact bonds :

9-10 9-13 10-11 11-12 11-14 12-13

isolated ring systems :

containing 1 : 9 :

G1:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS9:Atom 10:Atom 11:Atom 12:Atom 13:Atom  
14:CLASS